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Objective: The primary aim of this study was to better understand the role of depressive and 
negative symptoms in patients with schizophrenia.  As such, two specific research questions 
guide this analysis: (1) What factors are associated with depressive and negative symptoms at 
Time 1 across four major psychiatric diagnoses (patients with schizophrenia, mood disorder, 
both schizophrenia and mood disorders, and patients who e primary diagnosis is neither 
schizophrenia nor mood disorder)? (2) To what extent do depressive and negative symptoms 
improve over time among individuals with schizophrenia? More specifically, what variables 
predict an improvement in these symptoms? 
Methods: The study involved analysis of secondary data from 3269 in-patients from 15 
psychiatric facilities in the Province of Ontario, Canada. Patients were assessed using the 
Resident Assessment Instrument – Mental Health (RAI-MH).   Bivariate analyses were 
performed examining demographic, clinical, social, and other factors as independent 
variables and depressive and negative symptom scores among each of the four diagnostic 
groups: schizophrenia, mood disorder, both schizophrenia and mood disorder, and neither 
schizophrenia nor mood disorder.  Logistic regression of depressive and negative symptoms, 
as dependent variables, were performed on demographic, psychiatric, clinical, social, and 
other variables, as the independent variables.   
Results: Variables associated with depressive and negative symptoms did not necessarily 
predict an improvement of depressive and negative symptoms over time.  Findings from 




depressive and negative symptoms included the following variables:  (1) not having a 
diagnosis of schizophrenia; (2) insight into one’s condition; (3) fewer number of recent 
psychiatric admissions (over the last two year period); and (5) being administered both 
atypical and typical antipsychotic medications.  
Conclusions: Depressive and negative symptoms are prevalent in schizophrenia and are 
associated with demographic, psychiatric, and social variables. Depressive and negative 
symptoms do not share the same pattern across diagnoses, suggesting that these symptoms 
represent a unique profile within each diagnostic group.  Moreover, both atypical and typical 
antipsychotic medications, in combination, were shown to be more effective at treating 
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Schizophrenia impacts upon behaviour, perception, and cognition, and seriously impairs 
activities of daily living.  The severity and chronicity of schizophrenia has led to a detailed 
examination of the socio-demographic and clinical variables that predict improved outcome.  
Similarly, it is important to clarify the antecedents of poor outcome amongst individuals with 
schizophrenia (Kay & Murrill, 1990).  As such, the presence of depression is an important 
predictor of the outcome and clinical course in schizophrenia.  Since depressive symptoms 
are common among patients with schizophrenia, it is important to note that it is often difficult 
to distinguish some of the clinical features of schizophrenia from depression. This is because 
the initial stage of schizophrenia (i.e., the prodrome of schizophrenia) may resemble 
depression (Birchwood, Iqbal & Upthegrove, 2005; Siris, 2000; Wassink, Flaum, Nopoulos, 
& Andreasen, 1999).  Unfortunately, depression still remains poorly understood in 
schizophrenia even if it is common among patients wi h schizophrenia.   
The presence of depressive symptoms in schizophrenia was first reported by Kraepelin in 
1971 (Howells, 1991).  Even though there is strong support for the concept of depression in 
schizophrenia, there is great difficulty in consistently measuring depression in schizophrenia.  
In a review conducted by Fleischhacker (2002), prevalence studies report widely varying 
numbers in rates of depression in those with schizop renia, ranging from as low as 7% to as 
high as 75%, depending on the diagnostic criteria used and the research sample studied, with 
a modal prevalence rate of 25% (Siris, 2000).  To compare, 7.9 to 8.6% of Canadian adults 




reported rates is most commonly attributed to the numerous, diagnostic criteria available to 
assess symptoms, the frequency of follow-up, and the variations in the patient’s environment 
(Birchwood, Iqbal & Upthegrove, 2005).  Moreover, the use of depression rating scales blur 
the distinction between the symptoms of depression and the negative symptoms of 
schizophrenia (Peralta, Cuesta, Martinez-Larrea & Serrano, 2000).  Another reason for the 
inconsistency in rates of depression is because ther is a problem of using scales in 
populations for which they were not designed (Addingto , 1996).  Moreover, the divergence 
in depression rates is also due to different diagnostic criteria (i.e., DSM-IV, RDC, or ICD-
10).  Furthermore, it is important to note that many patients who go on to develop 
schizophrenia “pass through” the diagnosis of a mood disorder early on in their illness 
(Wassink, Flaum, Nopoulos, & Andreasen, 1999). Wassink and colleagues (1999) believe 
that this reflects a clinical bias when facing uncertainty, and that it is better to diagnose 
depression than schizophrenia because of more favour ble prognosis and response to 
treatment, and the lesser stigmatization of affectiv  illness.  
Despite the frequency of depressive features in schizop renia, less is known about the 
precise nature and course of these symptoms.  The cluster of symptoms that are common in 
these individuals include negative symptoms, extrapyr midal symptoms, and cognitive 
changes.   It is therefore important to understand depressive symptoms in schizophrenia as it 
has been associated with increased personal stress (Kay, 1991), poorer functional 
performance (Kay, 1991; Whitehead, Moss, Cardno & Lewis, 2003), high rates of relapse 
(Collins, Remington, Coulter & Birkett, 1996; Whiteh ad, Moss, Cardno & Lewis, 2003), 




Happell, 2003; Rocca et al., 2005) compared to indiv duals with schizophrenia with no 
depressive symptoms.  
Many studies have illustrated that the course of the schizophrenic illness differs between 
men and women, but other studies have found no difference (Siegel, Irani, Brensinger, 
Kohler, Bilker, Ragland, et al., 2006).  Kay and Murrill (1991) identified several clinical 
predictors for better outcome in individuals with schizophrenia.  For example, good response 
to treatment has been related to a healthy premorbid adjustment, a sudden and clearly 
precipitated onset of illness, duration of less than two years, and a psychiatric profile of 
atypical and catatonic symptoms with the absence of emotional blunting.  The previous 
course of illness and the absence of depression are of c ucial importance for prognosis (Maj, 
Starace & Kemali, 1987).  Moreover, Glick and colleagues (2001) noted that adherence was 
an especially important challenge in the treatment of schizophrenia because paranoid 
symptoms can lead to mistrust of the treating physician, as well as the family.  These same 
authors also acknowledged the importance of individual psychotherapy to help the person 
cope with the illness. 
It is well recognized that there is a challenge in differentiating between depressive 
symptoms, negative symptoms, and extrapyramidal sympto s (EPS) because they all share 
common features.  The term “negative symptoms” refers to problems such as poverty of 
speech, impoverished ability to express emotion, and l ck of motivation. Extrapyramidal 
symptoms are often produced because of prolonged use of antipsychotic medication; the 
symptoms include tremors, muscle rigidity, drooling, eyes rolling upwards toward the 




gait (Noll & Nayer, 2000).  Escamilla (2001) notes hat a diagnosis of depression in the 
context of a chronic psychotic disorder is not easy because several of the symptoms that 
typically constitute a depressive disorder may actully be negative symptoms of 
schizophrenia or side effects of an antipsychotic medication.  For example, social 
withdrawal, apathy, and anhedonia often represent the clinical profile of someone with major 
depression, but these symptoms are also seen in thecont xt of negative symptoms and drug-
induced side effects.  Therefore, there are considerabl  problems in attempting to define 
symptoms of depression in schizophrenia because: (1) there is the possibility of confusing 
negative symptoms, such as apathy, blunted affect, and withdrawal, as seen in schizophrenia, 
with depression; and (2) EPS and other side effects of antipsychotic medications mimic signs 
and symptoms of depression (See Table 1).   
 Despite the inconsistencies in measuring depressiv ymptoms in schizophrenia 
because of the varying definitions employed, depressiv  symptoms are still prevalent and 
more research needs to be done to better understand the course of these symptoms in 
individuals with schizophrenia.  Anhedonia, the diminished capacity to experience pleasant 
emotions, is a frequent, treatment-resistant featur of schizophrenia that is often included 
among the negative symptoms of the disorder (Horan et al., 2006).  When depression is 
present in an individual afflicted with one of the psychotic disorders it is considered a 
dangerous sign.  For example, suicide is far more likely to result from depression in 
psychotic individuals.  Indeed, about 10% of all individuals with bipolar disorder (manic-
depressive psychosis) and an equal percentage of those diagnosed with schizophrenia commit 




who also suffer from depression, commit suicide (Siris, 2000).  Moreover, studies have 
shown individuals with schizophrenia are most likely to commit suicide within the first 10 
years of the onset of the disease. This depression may be caused by the “underlying 
schizophrenic disease process, the realization by the person that his or her mental capacities 
are deteriorating, or as a side effect of antipsychoti  medication” (Noll & Nayer, 2000). Forty 
percent of patients with schizoaffective disorder commit suicide at some time in their lives 
(Potkin et al., 2003).  The percentage of those whocommit suicide is strikingly higher in the 
schizoaffective population than the schizophrenia group because of the presence of more 
severe mood-related symptoms.   
Depression and schizophrenia are both common psychiatri  illnesses that severely 
interfere with one’s livelihood and require intensive treatment. It is even more debilitating for 
individuals diagnosed with schizophrenia, who also suffer from depression. As such, the goal 
of this paper is to better understand depressive and negative symptoms in those individuals 
diagnosed with schizophrenia. 
1.1 Depression in schizophrenia: Affect, symptom, or syndrome? 
An important issue in the literature is the confusion and inconsistency in using the 
term “depression” in schizophrenia.  Many use the term depression to denote an affect, but 
some use it to denote a symptom or a syndrome.  Unfortu ately, it is not always clear which 
definition is employed in research studies.  Siris (2000) makes a distinction between the three 
different states. Depression as an affect is related to a subjective experience of sadness, 
caused by interaction with the internal or external environment.  The symptom of depression 




and wane so it does not warrant a diagnosis of depression.  In order to receive a diagnosis of 
depression, the person must experience depressed mood, or lack of interest or pleasure, and 
also have other symptoms associated with depression for at least 2 weeks.  The DSM-IV 
criteria for major depressive disorder are further explained in the next section.    
1.2 Diagnosis of major depressive disorder and schizophrenia 
Current research in the diagnosis of depression has focu ed on special populations 
and on identifying subtypes that may respond differently to treatment (Glick, Suppes, 
Debattista, Hu, & Marder, 2001).  Major depression is defined as having at least five 
symptoms during the same 2-week period, with marked changes in function [Diagnostics and 
Statistical Manual of Mental Disorders (DSM-IV), 1994]. Moreover, at least one of the 
symptoms must be depressed mood or loss of interest or pleasure.  At least three of the 
following must also be observed: weight, sleep, activity level, energy, ability to think or 
concentrate, or suicidal ideation.  A major task for clinicians is to differentiate major 
depression from depressed states caused by secondary factors, such as life stress, alcohol or 
medications, medical or psychiatric illness, or bereavement (DSM-IV, 1994; Glick et al., 
2001).   
According to the DSM-IV, there are two types of bipolar disorder: bipolar I and II.  
Patients with bipolar I have a history of depression and mania, whereas those with bipolar II 
have depression and hypomania.  Mania is defined as a di tinct period of abnormally 
elevated mood lasting at least 1 week, with symptoms f grandiosity, decreased need for 
sleep, racing thoughts, or excessive involvement in activities that have negative 




seriously impair functioning or require hospitalizat on.  Patients with bipolar I may also 
experience psychotic symptoms during unstable mood.  Differential diagnosis of bipolar 
disorder includes personality disorders, major depression, schizophrenia, and substance abuse 
disorders (Glick et al., 2001).   
The current understanding of schizophrenia emphasizes an underlying biological 
cause (Jeste, 1996; Noll & Nayer, 2000).  The DSM-IV defines schizophrenia as having two 
or more of the following symptoms during a 1-month period: delusions, hallucinations, 
disorganized speech, grossly disorganized or catatonic behaviour, and negative symptoms.  
The DSM-IV continues to emphasize the presence of psychotic symptoms (delusions and 
hallucinations) as well as social and vocational impairment, but has also broadened to include 
negative symptoms and cognitive deficits as seen in patients with schizophrenia.  Many 
authors acknowledge the importance of cognitive and negative symptoms because they have 
greater impact on long-term prognosis than psychoti symptoms alone (Glick et al., 2001; 
Jeste, 1996; Noll & Nayer, 2000).  Common differential diagnoses include bipolar disorder 
and substance abuse disorders. 
1.3 Bipolar Continuum Theory 
Many concepts have been suggested to explain the appearance of depression in 
schizophrenia. Depression has been viewed as a post-psychotic phase, as part of the 
psychotic process, or medication induced.  Recently, it has become accepted to view 
depression on the same spectrum as other mood disorder ; namely on a continuum of 
symptom severity, ranging from features of relatively mild depression and brief hypomania 




2003).  Kraepelin’s (Howell’s, 1991) assumption that manic-depression and schizophrenia 
are two distinct disorders is also being challenged, although many experts continue to support 
this theory. Proponents of the bipolar continuum theory support the concept of an expanded 
psychiatric continuum ranging from unipolar to bipolar disorder, to schizoaffective 
psychosis, to schizophrenia (Möller, 2003).  In addition, schizophrenia and bipolar disorder 
share certain epidemiologic characteristics, such as age of onset, lifetime risk, course of 
illness, worldwide distribution, risk of suicide, genetic influence, and genetic susceptibility 
(Möller, 2003; Noll & Nayer, 2000).  Therefore, there may be a subset of bipolar cases that 
represents a unique disease entity, while many cases fit into a bipolar-schizophrenia 
continuum.  However, the well-recognized diagnosis f chizoaffective disorder, which falls 
between schizophrenia and mood disorder, tends to add support for the continuum theory of 
mental illnesses.   
Schizophrenia and bipolar disorder do share many comm n features, but patients with 
schizophrenia primarily manifest disorders of thought rather than mood and have lower 
levels of social and vocational functioning between pisodes (Glick, Suppes, DeBattista, Hu, 
& Marder, 2001). Specifically, patients with bipolar disorder can have delusions during 
manic periods, but their delusions tend to be grandiose to match their mood, and thus, should 
resolve when the mania resolves (Glick et al., 2001).  Although schizophrenia and bipolar 
disorder share many common features, they are indeed separate disease entities, as classified 
under the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV, 
1994).  The Bipolar Continuum Theory is an interesting perspective in explaining the 




classification system for mental disorders. Until the DSM-IV classifies schizophrenia and 
bipolar disorder as a related disease, the Bipolar Continuum Theory should be viewed as 
merely an interesting concept, and thus more research is needed to support this theory.   
1.4 “Revealing depression” or post-psychotic depression in schizophrenia  
The occurrence of depressive symptoms during the chronic phase of schizophrenia 
has received much attention in recent years.  As such, Knights and Hirsch (1981) have coined 
the term “revealed depression” or post-psychotic depression to describe the unmasking of 
depression through the fading out of psychotic sympto atology.  It is evident that symptoms 
of psychosis may actually mask depressive symptoms hat persist, and are later “revealed” 
when the psychosis is successfully treated.  Unfortunately, Siris (2000) has argued that the 
term “post-psychotic depression” has been used to describe three similar, but clinically 
distinct, groups of patients. In the first definition, depressive symptoms are clearly evident 
during an acute psychotic episode and resolve as the positive psychotic symptoms resolve, 
although sometimes more slowly. These depressive symptoms only become apparent as the 
positive symptoms resolve, and the term “revealed depression” is sometimes applied. The 
second definition overlaps somewhat with the first, but describes patients who develop 
depressive symptoms as their positive psychotic sympto s resolve. The third definition 
states that depressive symptoms appear after the acut  episode has resolved. As such, the 
different definitions in the literature have blurred the concept of “revealed depression” in 
schizophrenia.  
Regardless, the concept of post-psychotic depression has now been incorporated into 




2000). The DSM-IV (1994) now suggests the term “post sychotic depression” be used to 
describe depression that occurs at any time after a psychotic episode in schizophrenia – even 
after a prolonged interval.   
1.5 The Stress-Vulnerability Model of depression  
Stress-vulnerability models of schizophrenia propose that stressful life events may act 
as triggers of onset or relapse of psychotic symptos in schizophrenia (Siris, 2000).  The 
stress vulnerability model presumes a genetic vulnerability to schizophrenic psychosis, which 
is clinically apparent if triggered by a stressor. Si is also argues that depression could be such 
a stressor which is strong enough to induce a psychotic relapse. This assumption also 
explains why depression as a prodromal syndrome leads to psychosis. It is now apparent that 
the prodromal and early stages of psychosis are antecedents for the development of the long-
term illness trajectories and disabilities, as seen in schizophrenia; emotional dysfunction and 
depression are a key part of these early symptoms (Birchwood, Iqbal & Upthegrove, 2005).  
Depression is a highly stressful state psychologically; s such, depression could act as a 
sufficient stressor to precipitate psychosis in peopl  with schizophrenia.  The stress in the 
model can also be biological or psychosocial, such as viral infection or substance abuse.   
1.6  Psychotic depression, non-psychotic depression, and schizophrenia 
The clinical characteristics of individuals with psychotic depression, non-psychotic 
depression, and schizophrenia are different. Individuals with psychotic depression show 
symptoms of depression during an episode of psychosis, whereas those with non-psychotic 




schizophrenia, the clinical course of depressive symptoms is unclear.  Many researchers have 
presented evidence that psychotic depression is clinica ly and biologically distinct from non-
psychotic depression (Jeste, Heaton, Paulsen, Ercoli, Harris, et al., 1996).  They conclude 
that psychotic depression and non-psychotic depression hould be separate diagnoses; but, 
the DSM-IV still classifies the two disorders under major depression, with or without 
psychotic features.  Similarly, psychotic depression and non-psychotic depression are 
separate from the diagnosis of schizophrenia.   
1.7 Role of antipsychotic medications in observed depression 
Previously, the primary goal in the treatment of schizophrenia is successfully 
managing and controlling positive symptoms. However, r searchers have acknowledged the 
importance of controlling all symptom domains, such as improving compliance and 
preventing relapse, reducing side effects, and improving functional outcomes (De Nayer et 
al., 2003).  While antipsychotic drugs are very effective for the positive symptoms of 
schizophrenia, the treatment of negative symptoms is still unclear (Möller, 2004; Rummel, 
Kissling & Leucht, 2005).  As a result, atypical antipsychotics were introduced to treat the 
symptoms of schizophrenia because these drugs caused significantly fewer extrapyramidal 
symptoms (EPS) than traditional drugs and are more effective in treating both the negative 
and cognitive symptoms (Möller, 2004; De Nayer et al., 2003).   
Another controversial issue is whether or not antipsychotics induce a depressive 
mood or predispose recipients to depressive states among patients with schizophrenia. 
Antipsychotics, especially traditional compounds, may induce syndromes which mimic 




with extrapyramidal side-effects of akinesia1 and akathisia2.  Specifically, the touchstone of 
whether these symptoms are due to parkinsonism rather than to depression is the presence or 
absence of akinesia, or extrapyramidal symptoms (Escamilla, 2001).   
Atypical antipsychotics are a relatively new class of drugs, which are often used to 
treat the symptoms of psychosis. According to Noll and Nayer (2000), these drugs are called 
“atypical” because: (1) they are less likely to cause the serious neurological side effects (i.e., 
extrapyramidal side effects or EPS) than the older class of conventional antipsychotics; and 
(2) they significantly reduce both the positive, and to some extent, the negative symptoms of 
schizophrenia.  There is growing evidence to suggest that many patients with schizophrenia 
now report a more positive attitude toward atypical antipsychotics than the conventional 
antipsychotics (Möller, 2005a).  Specifically, there are fewer side effects, such as depression 
and apathy.  These authors suggest that atypical antipsychotics should be preferred to 
traditional ones to: (1) avoid pharmacogenic depression and (2) treat depressive features of 
schizophrenia (Möller, 2005a).  However, in a recent meta-regression analysis, there is no 
clear evidence that atypical antipsychotics are more effective or are better tolerated than 
conventional antipsychotics (Geddes, Freemantle, Harrison, & Bebbington, 2000; Kapur & 
Remington, 2001).  
Controlled studies on depression in patients with schizophrenia involving treatment 
with the atypical antipsychotic risperidone found that patients scored better on depression 
                                                   
1 Impaired body movement; without movement (or without m ch movement).  
2 A movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion as 
well as by actions such as rocking, crossing the legs while sitting, etc. People with akathisia are unable to sit or keep still, 





scales than those treated with the conventional antipsychotic haloperidol (Azorin, 1995; 
Ceskova & Svestka, 1993).  Moreover, the atypical antipsychotic olanzapine was found to be 
superior to risperidone with respect to scores on depression scales and rate of suicide 
attempts (Tran et al., 1997; Tollefson, 1999).  However, no difference in depressive 
symptoms were found between risperidone- (atypical) and haloperidol- (traditional) treated 
patients in other studies (Moller et al., 1995; Peusk ns, 1995).   
Patients treated with 10-15 mg/day of olanzapine improved significantly more than 
the placebo-treated patients on depression and anxiety scales, whereas patients treated with 
haloperidol or a lower dose of olanzapine did not (Beasley et al., 1996; Tollefson et al., 
1998).  The atypical antipsychotic ziprasidone was also found to be more effective in treating 
depression than placebo-controlled participants (Keck et al., 1998; Tandon et al., 1997; 
Daniel et al., 1999).  In addition, after treatment with the atypical antipsychotic clozapine, 
suicide rate fell from 25% to 3.5% in neuroleptic resistant patients. (Meltzer & Okayli, 
1995).  Mortality rate from suicide was also lower in current clozapine users than in past 
users (Walker et al., 1998).   
In another study conducted by Haro and Salvador-Carulla (2006), the investigators 
collected data from 10 European countries, involving 10, 972 patients changing or initiating 
antipsychotic medications. Findings show that patients in whom treatment was initiated with 
the atypical antipsychotic medications olanzapine or cl zapine or who started on more than 
one antipsychotic of any class at baseline tended to have somewhat greater improvement than 
patients treated with atypical (i.e., olanzapine or cl zapine) or typical antipsychotics (in 




negative symptoms to a greater extent than the typical agents, either by reducing secondary 
negative symptoms or by a direct effect on the prima y negative symptoms. Overall, the 
researchers showed: (1) atypicals confer a lower risk for tardive dyskinesia; (2) EPS are a 
predictor of later tardive dyskinesia, providing opp rtunities for risk reduction in the 
population exposed to antipsychotics (see Haro & Salvador-Carulla, 2006; Jeste, 2004). 
There appears to be support for both atypical and typical antipsychotic medications; as such, 
additional research needs to be done, especially controlled studies, in order to test the 
hypothesis of whether atypical antipsychotic medications are related to less EPS or whether 
atypical antipsychotic medications are related to less negative symptoms.   
1.8  Differentiating between symptoms of depression and negative symptoms of 
schizophrenia 
Negative symptoms of schizophrenia are often referrd to as the “deficit syndrome” 
(Howells, 1991).  Lately, attempts have been made to incorporate the idea of primary versus 
secondary negative symptoms.  Recent studies of negativ  symptoms in schizophrenia 
involve the deficit syndrome has focused on uncovering the symptoms that are primary to the 
disease rather than secondary to the psychotic process (Kelley, van Kammen, & Allen, 
1999).  A primary negative feature of schizophrenia is nhedonia. To recapitulate, anhedonia 
is the diminished capacity to experience pleasant emotions (Horan, Kring, & Blanchard, 
2006).  However, the negative symptoms of schizophrenia overlap with the syndrome of 
depression in a number of important respects (Siris, 2000). For example, loss of interest or 
pleasure, lack of motivation and energy, psychomotor retardation, and lack of concentration 




distinguishing.  For example, blunted affect suggests negative symptoms, whereas a low 
mood or cognitive features such as guilt or suicidal thoughts suggest depression.   Stones and 
Kirkpatrick (2003) argue that depression can present itself in three ways. The individual can 
show symptoms of anhedonia, dysphoria (a depressed moo ), or both.  The authors illustrate 
that dysphoria is often easy to detect because symptoms include negative statements, 
frequent complaints, sad thoughts, and unhappy behaviour or facial expression. However, 
anhedonia is not as easy to detect because their symptoms are often overlooked by caregivers 
(e.g., loss of interest or pleasure).  The interest in negative forms of schizophrenia has risen 
recently due to the fact that these subtypes have been associated with worse prognosis and 
poorer global adaptation than non-deficit forms of chizophrenia (Penadés, Gastó, Boget, 
Catalán, & Salamero, 2001).   
Kulhara and Chadda (1987) conducted one of the first studies assessing the 
occurrence of negative symptoms in patients with major depression and compared them with 
a group of patients with schizophrenia.  Two findings emerged from this study: (1) not all 
patients with schizophrenia have negative symptoms; and (2) even patients with 
schizophrenia who were identified on the basis of severity of negative symptoms cannot be 
differentiated from patients with major depression on the basis of total negative symptom 
scores. Since then, several authors have noted that al ough anhedonia and depression may 
be difficult to differentiate clinically, many factor analytic studies indicate that they form 
separate factors in patients with schizophrenia (Blnchard & Cohen, 2006; Horan et al., 




difficult if the patient lacks the interpersonal communication skills to properly articulate their 
internal subjective states (Siris, 2000).   
1.9  Treatment of schizophrenia with depressive symptoms 
Many different types of medications have been offered to treat depressive symptoms 
associated with schizophrenia. They include: 
Antipsychotics (Neuroleptics). Antipsychotic medications have shown improvements 
in treating depressive symptoms in patients with schizophrenia (Dufresne, Valentino, & 
Kass, 1993; Kramer et al., 1989; Dufresne, Kass, & Kecker, 1988).  
Atypical antipsychotics.  More recently, atypical antipsychotic medications have been 
used in this population.  To recapitulate the findings in this literature, patients treated with 
olanzapine had greated improvements in depressive symptoms than those treated with 
haloperidol (Tollefson et al., 1998). Marder and colleagues (1997) reported that in patients 
with chronic schizophrenia, olanzapine was more effctive than haloperidol in improving all 
symptom factors, including depression and anxiety.  Melzer and Okayli (1995) reported that 
patients with a history of suicidal ideation experienced a decrease in suicidal and depressive 
ideation when treated with olanzapine.   
Antidepressants. Kramer and colleagues (1989) found no difference between 
combinations of antidepressants and neuroleptics compared to neuroleptics alone in treating 
depression in patients with schizophrenia.  However, others have found that antidepressants 
combined with neuroleptics improved depressive sympto s (Hogarty et al., 1995; Prusoff et 




Lithium.  Lerner and colleagues (1988) found that lithium combined with haloperidol 
were related to improvements on scores of depression than those given haloperidol with a 
placebo.   
Although many different medications have been used to treat depressive symptoms in 
individuals with schizophrenia, this paper will only focus on atypical and typical 
antipsychotic medications because they are predominantly used in the schizophrenia 
















2. Common Tools Used for Measuring Depression 
Many depression scales have been employed without considering whether their 
content relates to the accepted definitions of depressive disorder (Addington, Addington, & 
Atkinson, 1996).  There is great concern in using depression scales in populations for which 
they were not designed, such as schizophrenia (Addington & Addington, 1996).  Despite the 
concern, common depression scales will be reviewed in order to better understand the 
psychometric properties and items within each scale, which will assist in determining the 
appropriateness of each scale in the schizophrenia population.  Since the analyses in this 
paper are guided by the Depression Rating Scale (DRS) and Negative Symptom Scale (NSS) 
in the Resident Assessment Instrument – Mental Health (RAI-MH), it is therefore important 
to examine the scales that the DRS and NSS were validated against.  Moreover, there are no 
published reports on the validity of the NSS; as such, this section will provide only an 
overview of the tools in which the DRS was validated against. It is also important to note that 
these tools are used in screening for and measuring the frequency and severity of depression, 
not in making a diagnosis of depression.   
2.1 Beck Depression Inventory (BDI) 
Description 
The patient checks 21 four-choice statements present d on a single page for the 
choice or choices most appropriate to him or her (Se Appendix 2).  The statements refer to 
the following areas: sadness, pessimism/discouragement, sense of failure, dissatisfaction, 




irritability, social withdrawal, indecisiveness, unattractiveness, work inhibition, insomnia, 
fatigability, loss of appetite, weight loss, somatic preoccupation, and loss of libido.  Scores 
range from 0-63; scores between 0-9 indicate no depression; 10-15 indicate minimal 
depression; 16-19 mild to moderate depression; 20-29 moderate to severe depression; and 30-
63 severe depression (Spreen & Strauss, 1998, p. 605).   
Comment 
Test-retest reliability with 38 patients was above .90, and changes in scores tended to 
follow changes in depth of depression for the individual patient (Beck, 1988).  Spearman-
Brown reliability was .93 and internal consistency for test items .86 (Spreen & Strauss, 
1998).   
Depression has been recognized as a multidimensional disorder.  Spreen & Strauss 
(1998), for example, extracted three factors (ideation depression, physiological depression, 
behavioural depression) from the BDI, and Brown et al. (1995) found five (i.e., negative self-
focus, anhedonia, sleep, weight loss, decreased libido).  
One disadvantage of this test is its obvious face validity, which is also apparent to the 
patient and hence makes dissimulation or feigning easy.  However, it is not clear whether 
self-administration or administration by an examiner leads to different results. For use in a 
neuropsychological setting, it should be noted thate BDI is not specifically designed to 
evaluate depression in elderly populations, and its value for the differential diagnosis of 
dementia versus depression has not been established.   
The BDI is just one of several depression scales developed to detect depression in 




administration, scoring, and interpretation.  Brink and colleagues (1982) recommends the use 
of the Geriatric Depression Scale for elderly patients instead of the BDI.   
2.2 Geriatric Depression Scale (GDS) 
Description 
The GDS consists of 30 Yes/No questions designed for self-administration (See 
Appendix 3).  The directionality of answers scored for depression changes randomly.  The 
purpose of the scale is partially disguised by the title “Mood Assessment Scale” at the top of 
the questionnaire. The GDS has been tested and used extensively with the older population.  
Score ranges from 0 to 30; scores of 0 to 9 are considered normal, 10 to 19 indicate mild 
depression, and 20 to 30 indicate severe depression.  
Comment 
The GDS may be used with healthy, medically ill and mild to moderately cognitively 
impaired older adults. It has been extensively used in community, acute and long-term care 
settings.  The GDS was found to have a 92% sensitivity and a 89% specificity when 
evaluated against diagnostic criteria (Spreen & Strauss, 1998). The validity and reliability of 
the tool have been supported through both clinical pr ctice and research.  The GDS is not a 
substitute for a diagnostic interview by mental health professionals.  It is a useful screening 
tool in the clinical setting to facilitate assessment of depression in older adults especially 
when baseline measurements are compared to subsequent scores. 
Spreen and Strauss (1998) found the GDS to be useful in elderly subjects with 
physical illness.  Moreover, discrimination between mildly demented depressed and non-




versus depression was also investigated; depressed demented elderly scored higher on the 
scale than non-depressed demented elderly (Spreen & Strauss, 1998).   
 The GDS was developed specifically for elderly subjects.  It deliberately omits items 
dealing with guilt, sexuality, and suicide, which the authors considered inappropriate for 
elderly subjects.  It includes items dealing with perceived locus of control that makes this test 
more suitable for hospitalized and long-term care subjects. The Yes/No format makes fewer 
demands on the cognitive skills of the patient and lea s to better completion rates than point-
scales like the BDI in clinical populations with cognitive impairment (Dunn & Sacco, 1989).   
2.3 Cornell Scale of Depression in Dementia (CSDD) 
Description 
The Cornell Scale for Depression in Dementia (CSDD) was developed specifically to 
assess signs and symptoms of major depression in dementia on the basis of a semi-structured 
interview of a qualified informant (See Appendix 4).  The CSDD evaluates a broad spectrum 
of depressive signs and symptoms and includes items fro  other depression scales.  This is a 
19-item clinician-administered instrument that uses information obtained from interview of a 
caregiver (a method suitable for patients with dementia) as well as from direct observation 
and interview of the patient. Scores range from 0-38, with <6, >10, and >18 indicating 
normal, probable major depression, and definite major depression, respectively.  
Comment 
The scale has high inter-rater reliability (0.67), internal consistency (coefficient alpha 
= 0.84), and sensitivity (Alexopoulos, 1988).  The CSDD was developed for use in demented 




history and reliable symptom reporting.  Because negative symptoms of schizophrenia are 
related to the cognitive deficits, this scale is often used in the schizophrenia population 
(Harvey, Koren, Reichenberg, & Bowie, 2005). Studies have suggested that information 
gathered by outside sources reveals more depressive symptoms than dementia patients admit 
themselves (Spreen & Strauss, 1998).   One community survey study instructed caregivers to 
fill out traditional depression scales to show that caregivers are reliable reporters of 
depressive symptoms in patients with Alzheimer's disease.  The CSDD is an interviewer-
administered scale that uses information both from the patient and an outside informant.  The 
scale has correlated well with depression as classified by the Research Diagnostic Criteria 
(RDC) [Spreen & Strauss].  Factor structure analysis reveals 4 to 5 factors that are assessed 
by the CSDD, including general depression, biologic rhythm disturbances, 
agitation/psychosis, and negative symptoms.  However, v n the CSDD has been better 
validated in patients with mild to moderate dementia, compared with patients with severe 
dementia.   
2.4 Hamilton Depression Rating Scale (HAMD) 
Description 
 The HAMD is a 17-item clinician administered scale that evaluates depressed mood, 
vegetative and cognitive symptoms of depression, and comorbid anxiety symptoms (See 
Appendix 5).  Some items are defined in terms of a series of categories of increasing 
intensity, while others are defined by a number of equal-valued terms (Hamilton, 1960). The 
variables are measured either on a 3-point or a 5-point scale. In general, the 5-point scale 




severe; 4=very severe.  The 3-point scale items use a rating of 0=absent; 1=probable to mild; 
2=definite. Also, there is no distinction between frequency or intensity of symptom; the rater 
has to consider both when making a judgment (Hamilton, 1960).  Scores range from 0 to 54, 
with 10-13, 14-17, and 17+ indicating mild, mild to moderate, and moderate to severe, 
respectively.   
Comments 
 The HAMD was one of the first scales developed to measure the severity of 
depressive symptoms. The psychometric properties of the scale have been well documented.  
It is often helpful to have more than one rater administer this scale for the purpose of 
reliability (Hamilton, 1960).  The scale has high inter-rater reliability (0.90) (Hamilton). 
However, many studies have been conducted since then that criticized the psychometric 
properties of the HAMD.  Bagby and colleagues (2004) conducted a thorough systematic 
review of the HAMD since 1979.  Although the internal, inter-rater, and retest reliability 
estimates of the HAMD are good (as are convergent, discriminant, and predictive validity); 
however, at the item level inter-rater and retest coefficients show that the items may be 
problematic, which lead to poor content validity (Bagby, Ryder, Schuller & Marshall, 2004).  
Since the scale items do not adequately measure the severity of depression, the authors 
concluded that the HAMD is psychometrically and conceptually flawed and should not be 
considered the “gold-standard depression scale”.  As such, the DRS is being validated against 
the BDI (Hirdes et al., in press).   





The DRS is a clinical indicator of possible depression, based on the following 7 
items: negative statements, persistent anger, expressions of unrealistic fears, repetitive health 
complaints, repetitive anxious complaints, facial expr ssion, and crying or tearfulness.  DRS 
score is a summed score of the 7 items, and may vary between 0 and 14, where a score of 3 
or more is considered to be indicative of possible depression, and a score of 6 or more to 
indicate more severe depression (Burrows et al., 2000) (See Appendix 6a). 
Comment 
In a study between DRS and GDS, the correlation was 0.13 (Anderson et al., 2003).  
These authors suggested that the DRS may be of limited clinical value to identify depression 
among older adults living in nursing homes.  However, in another study conducted by 
Koehler and colleagues (2005) suggest that the Minimum Data Set depression items and 
GDS identify different elements of depression.  Moreover, the GDS is a self-administered 
scale, whereas the Minimum Data Set depression scale is observer-rated; there may be 
inherent differences in the reporting nature between th  two sources.  In another study 
conducted by Burrows and colleagues (2000), they showed that a cut-point score of 3 on the  
DRS maximized sensitivity (94% for Hamilton Depression Scale, 78% for CSDD) with 
minimal loss of specificity (72% for Hamilton Depression Scale, 77% for CSDD) when 
tested against cut-offs for mild to moderate depression in the derivation sample.  Koehler and 
colleagues (2005) concluded that the DRS and GDS may identify different elements of 
depression, which may be due to differences in the “manifest symptom content and/or the 
self-report nature of the GDS compared to the observer-rated DRS.  However, Burrows and 




used to screen for depression in nursing home residents.   Moreover, the DRS has been 
validated in the schizophrenia population (Chalis, unpublished).   
In reviewing these depression scales, several researchers have found limitations in the 
DRS.  For example, Stones and colleagues (2003) have found that anhedonic symptoms are 
equally important to the dysphoric symptoms of depression.  As such, it is important to 
measure both depressive and negative symptoms because it provides valuable information on 
















3. Study Rationale 
 The previous discussion has shown that depressive ymptoms are common in 
individuals with schizophrenia. However, little is known about the course of illness in these 
individuals.  Therefore, in order to better understand depressive symptoms in patients with 
schizophrenia, both depressive and negative symptoms need to be assessed not only in 
individuals with schizophrenia, but must also be compared across other diagnoses.  What 
factors are associated with depressive and negative symptoms at Time 1 across four major 
psychiatric diagnoses (patients with schizophrenia, mood disorder, both schizophrenia and 
mood disorders, and patients whose primary diagnosis is neither schizophrenia nor mood 
disorder)? Moreover, research to date has lacked information on whether depressive and 
negative symptoms change over time in this population. Since one of the datasets provides 
information on patients at two points in time, a trjectory of change (i.e., improvement) can 
be monitored for these individuals. To what extent do depressive and negative symptoms 
improve over time among individuals with schizophrenia? More specifically, what variables 
predict an improvement in these symptoms? Lastly, the li erature has shown inconsistencies 
in the relationship between atypical antipsychotic use and observed rates of depression.  
Many researchers believe that atypical antipsychoti medications should be preferred to 
avoid pharmacogenic depression and to treat depressive features of schizophrenia (e.g., 
Möller, 2005b).  However, other researchers have found no clear evidence that atypical 
antipsychotic medications are more effective or better tolerated than traditional 
antipsychotics (e.g., Geddes, Freemantle, Harrison, & Bebbington, 2006; Kapur & 




antipsychotic medications are better associated with an improvement in depressive and 





























  This study is an analysis of secondary data and was based upon cross-sectional and 
longitudinal data derived from the RAI-MH instrument. The analyses were computed on SAS 
9.1 version for Windows. 
4.1 Sample 
The sample is comprised of RAI-MH data collected from three projects funded by the 
Primary Health Care Transition Fund (PHCTF) in Ontario.  The PHCTF was funded by the 
Ontario Ministry of Health, from March 2004 to July 2006. The goal of the projects was 
threefold: (1) Refinement of mental health quality indicators (MHQIs); (2) Refinement of 
mental health assessment protocols (MHAPs); and (3) Derivation and/or validation of 
outcome measures based on the RAI-MH (validation).  All samples for the three projects 
were based on consecutive admissions (or those scheduled for routine re-assessment) of 
adults aged 18 and over in a designated psychiatric bed in the participating hospitals/units. 
Participating facilities were asked to contribute 100 assessments on average.  Participating 
units included those with acute, long-term, forensic, and geriatric psychiatry patients.  Based 
on the current literature, poor cognitive function can have an effect on depression rating and 
negative symptom scores (Harvey et al., 2006; Penades et al., 2001). As such, individuals 
with Cognitive Performance Scale (CPS) score of 3 or m re are excluded from all analyses in 
this paper [See CPS in section 4.5(c)]. 
 The subjects in these studies were inpatients of 15 psychiatric facilities (see Appendix 




impairment were excluded from the present study sample for the reason of sample 
homogeneity.  Each patient was assessed by a single mental health professional (e.g., nurses, 
social workers, psychiatrists, psychologists, family physicians, recreational or occupational 
therapists).  Each assessor received formal training on the use of the RAI-MH prior to the 
project’s initiation.  
4.2 What is the RAI-Mental Health? 
The Resident Assessment Instrument – Mental Health (RAI-MH) is a standardized 
and comprehensive instrument for evaluating psychiatric patient’s needs, strengths, and 
preferences in institutionalized settings (See Appendix 9; Hirdes et al., 2003; Hirdes et al., 
2002).  The RAI-MH has been a mandatory assessment system for all adult in-patient 
psychiatric beds in Ontario since October 2005.  TheRAI-MH encompasses the Minimum 
Data Set for Mental Health (MDS-MH) and Mental Health Assessment Protocols (MHAPs).  
According to Hirdes and colleagues (2003), the MDS-MH is a brief screening instrument that 
assesses key areas of function, including mental and physical health, social support, and 
service use.  Specifically, MDS-MH items identify patients who may benefit from additional 
evaluation of problems and risks for decline in health, well-being, or function (Hirdes et al., 
2003).   The MHAPs are “general guidelines for additional assessment and individualized 
care planning for patients who have the problematic trigger conditions” (Hirdes et al., 2003).  
Previous research has shown the RAI-MH to be a valid and reliable assessment instrument 




4.3 Study variables in the RAI-MH 
 The dependent variable for the first research question is depressive rating and 
negative symptom scale scores at Time 13.  The dependent variable for second research 
question is improvement of depressive and negative symptom scale scores from Time 1 to 
Time 24.  The following are independent variables used for descriptive and/or possible 
correlates of the dependent variables based on the curr nt literature.  The item in brackets 
represents where the item can be found in the RAI-MH instrument.   
4.3.1    Demographic variables 
Gender (BB1)5 was coded as a categorical variable 1=male, 2=female.  Age of patients was 
coded as a continuous variable for univariate analyses (e.g., means) in years, and was re-
coded as a categorical variable for bivariate analyses (i.e., <25 vs. 25+ years of age).   
4.3.2 Mental health service history variables 
Psychiatric provisional diagnoses (Q1) were obtained via chart diagnoses and were coded as 
either primary, secondary or tertiary.  Number of recent psychiatric admissions over the last 
two years prior to the RAI-MH assessment (DD1) was coded as a categorical variable as 0 = 
none, 1= 1-2, or 2 = 3 or more.  Age at first hospitalization (DD6) was coded as a categorical 
variable as 1 = 0-14, 2= 15-24, 3 = 25-44, 4 = 45-6, or 5 = 65+. 
                                                   
3 Time 1 refers to the first RAI-MH assessment the patient received. 
4 Time 2 assessment refers to routine 3-month follow-up assessment, discharge assessment, or assessment based 
on a significant change in the patient’s status (i.e., after a suicide attempt).  





4.3.3 Social relation variables 
Social relations and interpersonal conflict [patient reports having no confidant (O2a)] was 
coded as a categorical variable as 0 = no, or 1= Yes.  Social relations and interpersonal 
conflict [family reports feeling overwhelmed with te patient (O2b)] was coded as a 
categorical variable as 0 = no, or 1= Yes. Social rel tionship [visit by a long-standing social 
relation/family member (O6b) was coded as a categorical variable as 0 = no, or 1, 2, or 3= 
Yes.  Social relationship [telephone or email contact with a long-standing social 
relation/family member (O6c) was coded as a categorical variable as 0 = no, or 1, 2, or 3= 
Yes. 
4.3.4 Discharge readiness variable 
Patient has a support person who is positive towards discharge/maintaining residence in the 
community (P2b) is coded as a categorical variable s 0 = no, or 1 = yes. 
4.3.5 Medication-related variables 
Medications (R2 a–i) were coded as a categorical variable as either typical or atypical 
antipsychotic medication, or both.  As such, there were 12 typical antipsychotic medications 
and 4 atypical antipsychotic medications.  See Appendix 8 for a list of the antipsychotic 
medications.  Medication refusal (K2) was coded as a categorical variable as 0 = no or 1 = 
yes.   
4.3.6 Patient characteristic variables 
Current in-patient status at time of assessment (A3) has 6 possible categories, but for the 




involuntary. Involuntary in-patient status pertains to the following: application for psychiatric 
assessment (exclude forensics, informal, forensic, and other.  Current patient type (Q5) is 
also coded as a categorical variable as 1 = acute care, 2 = longer-term patient, 3 = geriatric 
psychiatry patient, and 4 = forensic. 
4.3.7 Therapy-related variables 
The RAI-MH assessment contains a number of items indexing received therapies. For 
example, individual therapy (L3a), group therapy (L3b), family therapy (L3c), and self-help 
group (L3d) are coded as a categorical variable as 0 = no therapy received, or 1 = any therapy 
received.  Adherence with treatment (L5) is coded as a categorical variable 0 = not adherent, 
and 1 = adherent. A person is adherent if a score of 0, 1, or 3 is given (refer to RAI-MH). 
4.3.8 Insight into mental health variable  
Degree of patient insight into his/her mental health problem (B2) is coded as a categorical 
variable as 0 = full, 1 = limited insight, or 3 = none.   
4.3.9 ECT variable 
Patient received Electroconvulsive Therapy (ECT )(L6  is coded as a categorical variable as 
0 = no, and 1= yes. A person received ECT if a score of 2, 3, or 4 is given (refer to RAI-MH).  
4.4 Variables created from the RAI-MH 
(a) Depression Rating and Negative Symptom Scale. DRS and NSS scores are grouped into 
one of four categories in order to have a more holistic representation of depressive 
symptoms:  




(2) Negative symptoms only (i.e., DRS 0-2 and NSS ≥ 1);  
(3) Depression only (i.e., DRS ≥ 3 and NSS = 0); and  
(4) Both depression and negative symptoms (i.e., DRS ≥ 3 and NSS ≥ 1).   
(b) Trajectory of change. A trajectory of change in depressive rating and negative symptom 
scale variable was created and is computed by subtracting the DRS and NSS score at Time 1 
from the DRS and NSS score at Time 2. As such, there will either be an improvement or a 
lack of improvement in depressive and negative sympto  scores from Time 1 to Time 2. The 
coding for Time 1 is as follows: 
(a) If DRS at Time 1 = 0, 1, or 2 AND NSS at Time 1 = 0, then DRS and NSS at Time 1 = 0 
(b)  If DRS at Time 1 = 0, 1, or 2 AND NSS at Time 1 ≥ 1, then DRS and NSS at Time 1 = 1 
(c) If DRS at Time 1 ≥ 3 AND NSS at Time 1 = 0, then DRS and NSS at Time 1 = 2 
(d) If DRS at Time 1 ≥ 3 AND NSS at Time 1 ≥ 1, then DRS and NSS at Time 1 = 3 
The coding for Time 2 is as follows: 
(a) If DRS at Time 2 = 0, 1, or 2 AND NSS at Time 2 = 0, then DRS and NSS at Time 2 = 0 
(b)  If DRS at Time 2 = 0, 1, or 2 AND NSS at Time 2 ≥ 1, then DRS and NSS at Time 2 = 1 
(c) If DRS at Time 2 ≥ 3 AND NSS at Time 2 = 0, then DRS and NSS at Time 2 = 2 
(d) If DRS at Time 2 ≥ 3 AND NSS at Time 2 ≥ 1, then DRS and NSS at Time 2 = 3 
(1) Lack of improvement - A lack of improvement in DRS and NSS scores is po sible in 
four circumstances:  
(a) If DRS and NSS scores at Time 1 = 3 and DRS and NSS scores at Time 2 = 3;  





(c) If DRS and NSS scores at Time 1 = 2 and DRS and NSS scores at Time 2 = 2 or 
3, and; 
(d) If DRS and NSS scores at Time 1 = 2 and DRS and NSS scores at Time 2 =1 
(2) Improvement - An improvement is noted in two circumstances: 
(a) If DRS and NSS scores at Time 1 = 3 and DRS and NSS scores at Time 2 = 0, 1, 
or 2; and 
(b) If DRS and NSS at Time 1 = 1 or 2 and DRS and NSS scores at Time 2 = 0. 
4.5 Scales embedded in the RAI-MH 
 The outcome measures embedded in the RAI-MH cover a variety of domains relevant 
to clinicians and care providers. The domains provide aluable information on the patient’s 
state and also provide additional information for ca e planning purposes.  All interRAI 
instruments contain several outcome measure scales: Cognitive Performance Scale (CPS) 
(Morris et al., 1994); Activities of Daily Living (ADL) Hierarchy Scale (Morris, Fries, 
Morris, 1999); Aggressive Behavior Scale (ABS); Pain Scale; Negative Symptom Scale 
(NSS), Depression Rating Scale (DRS) (Burrows et al., 2000), etc. (see www.interrai.org). 
For the purposes of the paper, only the DRS and NSS scales will be used.   
(a) The Depression Rating Scale (DRS) has been validated against both the Hamilton 
Depression Rating Scale and the Cornell Scale for dep ession severity. The DRS is a clinical 
indicator of possible depression, based on the following items: negative statements, persistent 
anger, expressions of unrealistic fears, repetitive health complaints, repetitive anxious 
complaints, facial expression, and crying or tearfulness. If left as a continuous scale, the DRS 




of possible depression, and a score of 6 or more to indicate more severe depression. As such, 
the DRS can also be coded as a categorical scale, where scores ranging from 0-2 indicate 
mild depression, 3-5 moderate depression, and 6+ severe depression.   
(b) The Negative Symptoms Scale (NSS) is an indicator of withdrawal, and is based on the 
presence of anhedonia, loss of interest, lack of motivation, and reduced interaction.  As a 
continuous scale, the NSS may vary between 0 and 8, where higher scores represent elevated 
levels of negative symptomatology.   
(c) The Cognitive Performance Scale (CPS) 
The CPS describes the individual’s cognitive status based on short-term memory, decision-
making, expression, and self-performance in eating.  Based on these 4 items, an algorithm is 
used to compute a 7-point scale; from intact (score=0) and borderline intact (score=1), to 
mild (score=2), moderate (score=3), and moderate-sev re impairment (score=4), to severe 
impairment (score=5) and very severe impairment (score=6).   
4.6 Research Questions 
4.6.1 What factors are associated with depressive a nd negative symptoms at Time 1 
across four major psychiatric diagnoses (patients w ith schizophrenia, mood disorder, 
both schizophrenia and mood disorders, and patients  whose primary diagnosis is 
neither schizophrenia nor mood disorder)?  
Statistical method: chi-square analysis 
Outcome Variable: DRS (absence vs. presence of depressive symptoms) and NSS (absence 
vs. presence of negative symptoms) scores at Time 1 






Current in-patient status at time of assessment (A3)
Number of recent psychiatric admissions over the last two years (DD1) 
Age at first hospitalization (DD6) 
Insight into mental health (B2) 
Therapies received in the last week (L3a-d) 
Adherence to treatment (L5) 
ECT treatment in the last week (L6) 
Medication refusal (K2) 
Patient reports having no confidant (O2a) 
Family overwhelmed with patient (O2b) 
Visit by a long-standing relation (O6b) 
Telephone with a long-standing relation (O6c) 
Patient has a support person (P2b) 
Current patient type (Q5) 
Receiving atypical antipsychotic medication 




Receiving both atypical and typical antipsychotic medication 
Cognitive Impairment (as measured by the Cognitive Performance 
Scale) 
Datasets: MHAPs, MHQI, and validation datasets  
Depressive symptoms are assessed based on the DRS criteria and are classified under 
three groups of severity: mild (0-2), moderate (3-5), and severe (6+).  In these analyses, the 
DRS is re-coded in one of two categories: <3 or ≥3 to indicate the absence or presence of 
depression. Negative symptoms are assessed with the Negative Symptom Scale (NSS). This 
scale is re-coded into two categories: 0 or 1+ to indicate the absence or presence of negative 
symptomatology.  The analysis for this section is ba ed upon four DRS and NSS categories: 
(1) DRS 0-2 and NSS = 0 (i.e., no depressive and no negative symptoms); (2) DRS 0-2 & 
NSS ≥ 1 (i.e., negative symptoms only); (3) DRS ≥ 3 and NSS = 0 (i.e., depressive symptoms 
only); and (4) DRS ≥ 3 and NSS ≥ 1 (i.e., both depressive and negative symptoms).   
Individuals who have a psychiatric diagnosis of schizophrenia as measured by item 
Q1(e) in the RAI-MH will be compared with the following provisional diagnostic groups 
mood disorders (Q1f), both schizophrenia and mood disor ers (Q1e and Q1f), and neither 
schizophrenia nor mood disorders (neither Q1e nor Q1f).  By doing so, a typology of DRS 
and NSS scores is developed between the different diagnostic subgroups. 
 Each of the independent variables are cross-tabulated with the dependent variable of 
DRS and NSS scores at Time 1 in order to see if there is an association between the 




independent variable and its relation to DRS and NSS scores at Time 1 across the four 
diagnostic groups. 
4.6.2 To what extent do depressive and negative sym ptoms improve over time among 
individuals with schizophrenia? More specifically, what variables predict an 
improvement in these symptoms? 
Statistical method: Chi-square test for bivariate analysis and logistic regression for 
multivariate analysis 
Outcome Variable: Improvement in DRS and NSS scores from Time 1 to Time 2 
Independent variables:   
Age (BB2) 
Current in-patient status at time of assessment (A3)
Number of recent psychiatric admissions over the also two years 
(DD1) 
Age at first hospitalization (DD6) 
Insight into mental health (B2) 
Therapies received in the last week (L3a-d) 
Medication refusal (K2) 
Patient reports having no confidant (O2a) 
Patient has a support person (P2b) 




Receiving atypical antipsychotic medication 
Receiving typical antipsychotic medication 
Receiving both atypical and typical antipsychotic medication 
   
Dataset: MHQI dataset 
 An “improvement in DRS and NSS scores from Time 1 to Time 2” variable is 
created. An improvement in DRS and NSS scores is obtained under two circumstances: (1) if 
DRS and NSS scores at Time 1 = 3 and DRS and NSS scores at Time 2 = 0,1, or 2; and (2) if 
DRS and NSS at Time 1 = 1 or 2 and DRS and NSS score  at Time 2 = 0. A decline in DRS 
and NSS scores is also possible in two circumstances: (1) if DRS and NSS scores at Time 1 = 
3 and DRS and NSS scores at Time 2 = 0; and (2) if DRS and NSS scores at Time 1 = 1 or 2 
and DRS and NSS scores at Time 2 = 1, 2, or 3. For the purposes of this research question, 
we will only look at the improvement in DRS and NSS scores.  
Each of the independent variables will be cross-tabulated with the dependent variable 
of improvement in DRS and NSS scores in order to see if there is an association between the 
independent and dependent variables.  Moreover, based on the results of the chi-square 
analyses, we can decide which variables to include in logistic regression models in order to 





(a) Descriptive statistics (e.g., frequency and percentage distributions; mean, and standard 
deviation) were used to describe the study sample.    
(b) Bivariate analyses (e.g., t-tests, cross-tabulations) were used to compare depressive 
symptoms in those who were diagnosed with schizophrenia and those who were not. 
Depressive symptoms will also be compared for those who use atypical versus typical 
antipsychotics.   
(c) Multivariate analyses (e.g., logistic regression) were used to test different independent 
variables and their relationship to the dependent variable of interest.  
(d) Regression diagnostics and overall model-fit were performed according to standard 





 Research Question 1: What factors are associated with depressive and negative 
symptoms at Time 1 across four major psychiatric diagnoses (patients with 
schizophrenia, mood disorder, both schizophrenia and mood disorders, and patients 
whose primary diagnosis is neither schizophrenia nor mood disorder)? 
5.1 Univariate analyses 
5.1.1 Sample demographics 
Univariate analyses (mean, standard deviations, N, and percentages) were used to 
describe the study sample on diagnosis, demographic, sy hiatric, and clinical 
characteristics.  
Table 1 provides a basic summary of the sample chara teristics of the patients who had a 
chart diagnosis of schizophrenia, mood disorder, both schizophrenia and mood disorder, and 
neither schizophrenia nor mood disorders.  In terms of diagnosis, 29.5% had a chart 
diagnosis of schizophrenia, 47.8% had a diagnosis of mo d disorder, 7.2% had a diagnosis of 
both schizophrenia and mood disorder, and 15.5% had neither a diagnosis of schizophrenia 
nor mood disorder.  
The mean age in years and standard deviation (SD) for each of the four groups are as 
follows: 43.7 (17.2), 46.6 (16.4), 45.9 (17.4), and 49.4 (21.5).  The percentage (n) of males in 




(263). The largest proportion of males is in the schizophrenia group, and the lowest 
proportion of males is in the mood disorders group.  
5.1.2 Depression Rating Scale and Negative Symptom Scale 
In terms of scores on the depression rating scale (DRS), a score of 3 or more indicates the 
presence of depressive symptoms, 39.2% (378) with schizophrenia scored 3 or more on the 
DRS compared to 55.8% (869) with a mood disorder, 42.5% (99) with a mood disorder and 
schizophrenia, and 43.5% (219) with neither a mood disorder nor schizophrenia.  On the 
negative symptom scale (NSS), a score of 1 or more indicates the presence of negative 
symptoms. Fifty percent (480) of individuals with schizophrenia scored 1 or more on the 
NSS compared to 54.8% (856) with mood disorders, 50.4% (118) with a mood disorder and 
schizophrenia, and 45% (227) with neither a mood disor er nor schizophrenia.  
DRS and NSS scores were also categorized into four gr ps: (1) neither depressive nor 
negative symptoms; (2) negative symptoms only; (3) depressive symptoms only; and (4) both 
depressive and negative symptoms. Table 2 shows that for those who had a diagnosis of 
schizophrenia, 36.2% (349) had neither depressive nor negative symptoms, 24.6% (237) had 
negative symptoms only, 14.1% (136) had depressive symptoms only, and 25.2% (243) had 
both depressive and negative symptoms.  Interestingly, the schizophrenia group had the 
highest percentage of negative symptoms only compared to the other three diagnostic groups.   
5.1.3 DRS and NSS scores at Time 1 and Time 2 
 Table 3 shows the DRS and NSS scores at Time 1 and Time 2 for those who had a 
diagnosis of no schizophrenia. As illustrated, in those with negative symptoms only at Time 




if the patient has both depressive and negative sympto s at Time 1, 44.6% improved to 
having neither of the symptoms at Time 2.  
A similar trend is seen in individuals with schizophrenia.  For example, if an 
individual had both depressive and negative symptoms at Time 1, 50.4% had neither of the 
symptoms at Time 2.  Similarly, those who had either depressive or negative symptoms at 
Time 1, 51.7% and 51.8%, respectively had neither of the symptoms at Time 2 (See Table 4). 
5.2 Bivariate analyses 
Bivariate analyses (i.e., chi-square test) were performed to examine what 
characteristics determined depressive and negative symptom scores at Time 1.  A total of 18 
independent variables were used to test its association with the dependent variable (i.e., DRS 
and NSS scores at Time 1).  There were two demographic variables (age and gender), two 
mental health service history variables (number of recent admissions and age at first 
hospitalization), two patient status variables (current in-patient status and current patient 
type), four social functioning variables (patient reports having no confidant, family reports 
feeling overwhelmed, visiting by a social relation, a d telephone with a social relation), two 
therapy-related variables (therapy, and adherence with treatment), four medication-related 
variables (medication refusal, atypical antipsychotic medication, typical antipsychotic 
medication, and both atypical and typical antipsychotic medications), one item on insight, 
and one variable on cognitive functioning (i.e., CPS).  A cut-off probability level of 0.10 was 




5.2.1  Demographic predictors 
 Table 5 shows the gender (BB1) distribution by the four DRS and NSS categories at 
Time 1, by the diagnosis of schizophrenia. For males, the majority of them had neither 
depressive nor negative symptoms, but 27.2% had negativ  symptoms only, 12.1% had 
depressive symptoms only and 23% had both depressive and negative symptoms. The 
majority of females (33.3%) also had neither of the symptoms, but 20.4% showed some 
negative symptoms, 17.6% showed depressive symptoms only, and 28.7% showed both 
depressive and negative symptoms.  Males had more negative symptoms, whereas females 
showed predominately depressive symptoms. Chi-square analysis of gender and the four 
levels of DRS and NSS scores by the diagnosis of schizophrenia was significant at the 0.02 
level.   
 Age (BB2) was also cross-tabulated with the four leve s of DRS and NSS scores by 
schizophrenia, and chi-square analysis was significa t at the 0.06 level.  Age was classified 
as early (age 18-25) or late onset (age 25+).  In those who had an early onset, 34.9% had 
neither of the symptoms, 32.9% had negative symptoms nly, 12.3% had depressive 
symptoms only, and 19.9% had both symptoms. In those who had a late onset, 36.4% had 
neither of the symptoms, 23.0% had negative symptoms nly, 14.6% had depressive 
symptoms only, and 26% had both symptoms.  Some interesting patterns are proposed: (1) 
those who had an early onset appeared to have more negative symptoms only than those who 
had a late onset; and (2) those who had a late onset app ared to have more depressive and 




Table 6 shows the gender and age cross-tabulations with the DRS and NSS categories, by 
the diagnosis of mood disorder.  Across the DRS and NSS scores, females appeared to show 
more depressive and negative symptoms than males. Females also appeared to have more 
depressive symptoms only than males, whereas males appeared to show more negative 
symptoms only than females.  In terms of age distribu ion, the pattern of depressive and 
negative symptoms is similar for both the early andlate onset groups. The highest percentage 
is in the both symptom group, followed by depressive symptoms, and negative symptoms 
only.   
Table 7 shows the DRS and NSS scores at Time 1 for age and gender, by the diagnosis of 
schizophrenia and mood disorder.  Gender was significa t at the 0.01 level, but age was not 
significant.  Once again, this suggests that females might have more depressive symptoms, 
whereas males might have more negative symptoms.   
Table 8 shows the DRS and NSS scores at Time 1 for age and gender, by the diagnosis of 
neither schizophrenia nor mood disorder.  Gender was significant at the 0.005 level, but age 
was not significant.  Males appeared to show more negative symptoms only and females 
appeared to show more depressive symptoms only. However, both males and females had a 
similar percentage of both symptoms.   
5.2.2 Mental health service history 
 Table 9 shows DRS and NSS scores at Time 1 and mental health service history 
(number of recent psychiatric admissions [DD1] and ge at first hospitalization [DD6]), by 
the diagnosis of schizophrenia. For those who had zero recent psychiatric admissions, 36.0% 




showed some negative symptoms only, 16.9% showed some depressive symptoms only, and 
23.8% showed both depressive and negative symptoms. Interestingly, as the number of 
recent psychiatric admissions increases, the percentag  of both depressive and negative 
symptoms also increases.  Chi-square analysis was significant at the 0.04 level.  Age at first 
hospitalization was also significant at the 0.06 leve . Some patterns are proposed from the 
cross-tabulations: (1) Those that exhibited negative symptoms only, 52.9% are in the 15-24 
age group, and 33.8% are in the 25-44 age group (2) The percentage of depressive symptoms 
only appear to be highest in the 15-24 and 25-44 age group; and (3) The percentage of 
depressive and negative symptoms appear to be highest in the 65+ age group.  Therefore, 
from these results, negative symptoms only and depressive symptoms only appear to be most 
prominent when the person is hospitalized between 15-44 years of age. The presence of both 
symptoms seems to be most prominent when the person is hospitalized at age 65+.   
 Table 10 shows DRS and NSS scores at Time 1 and metal health service history 
(number of recent psychiatric admissions and age at first hospitalization), by the diagnosis of 
mood disorder.  For those who had zero recent psychiatric admissions, 41.3% of individuals 
still presented both depressive and negative symptos.  For those who had one or two 
psychiatric admissions, a high percentage is still seen in the both depressive and negative 
symptom category (p=0.09).  Age at first hospitalization was also cross-tabulated with DRS 
and NSS scores, but was insignificant (p=0.17).    
Table 11 shows DRS and NSS scores at Time 1 and mental health service history 




both schizophrenia nor mood disorder.  However, neither variables were predictors of DRS 
and NSS scores at Time 1. 
Table 12 shows DRS and NSS scores at Time 1 and mental health service history 
(number of recent psychiatric admissions and age at first hospitalization), by the diagnosis of 
neither schizophrenia nor mood disorder.  Chi-square analysis of recent psychiatric 
admission and DRS and NSS was significant (p=0.03).  In those with zero recent psychiatric 
admissions, 39.7% had no depressive and no negative symptoms. In those with one or two 
recent psychiatric admissions, 41.4% had no depressive and no negative symptoms. 
However, in those with three or more psychiatric admissions, 34.4% had both depressive and 
negative symptoms.  Age of first hospitalization and DRS and NSS scores was also 
significant (p=0.02). Interestingly, both depressive and negative symptoms are prominent in 
the 25-44 age groups.   
5.2.3 Current inpatient status (A3) 
 Table 13 shows the percentage of involuntary and voluntary admissions across DRS 
and NSS scores by the diagnosis of schizophrenia. For those who had no depressive and no 
negative symptoms, 46.4% were admitted on an involuntary basis. For those who showed 
some negative symptoms only, 55.9% were admitted on an i voluntary basis. For those who 
showed some depressive symptoms only, 64% were admitte  on an involuntary basis. For 
those who showed both depressive and negative symptoms, 51.9% were admitted on an 
involuntary basis.  Chi-square analysis for inpatient status and DRS and NSS scores, by the 




 Table 14 shows the percentage of involuntary and voluntary admissions across DRS 
and NSS scores by the diagnosis of mood disorder. For those who had no depressive and no 
negative symptoms, 30.5% were admitted on an involuntary basis. For those who showed 
some negative symptoms only, 41.3% were admitted on an i voluntary basis. For those who 
showed some depressive symptoms only, 38.0% were admitte  on an involuntary basis. For 
those who showed both depressive and negative symptoms, 32.4% were admitted on an 
involuntary basis.  Chi-square analysis for inpatient status and DRS and NSS scores, by the 
diagnosis of schizophrenia was significant at the 0.002 level. The percentage for the presence 
of depressive and negative symptoms is higher for the patients diagnosed with schizophrenia 
than patients diagnosed with mood disorder. 
 Chi-square analysis of DRS and NSS scores at Time 1 and current inpatient status, by 
the diagnosis of schizophrenia and mood disorder was insignificant (p=0.16) (See Table 14). 
Similarly, chi-square analysis of DRS and NSS scores at Time 1 and current inpatient status, 
by the diagnosis of neither schizophrenia nor mood disorder was also insignificant (p=0.16) 
(See Table 16). 
5.2.4 Current patient type (Q5) 
 Table 17 summarizes the DRS and NSS scores at Time 1 and current patient type by 
the four diagnostic groups.  Chi-square analysis showed current patient type to be associated 
with DRS and NSS scores in three diagnostic groups: schizophrenia, mood disorder, and 
neither schizophrenia nor mood disorder (p<.0001). Acute patients in the schizophrenia 
group had mostly depressive and negative symptoms. Mo t of the longer-term, geriatric, and 




patients with a mood disorder, most acute types had both depressive and negative symptoms, 
most longer-term and geriatric patients had no depressive and no negative symptoms, and 
most forensic patients had negative symptoms only. I  those patients with both schizophrenia 
and a mood disorder, most acute patients had both depressive and negative symptoms, 
whereas the longer-term, geriatric, and forensic patients had mostly none of the symptoms.  
In those patients with neither schizophrenia nor a mood disorder, most acute patients had 
both depressive and negative symptoms, whereas the long r-term, geriatric, and forensic 
patients had mostly none of the symptoms.   
5.2.5 Social functioning 
 Table 18 displays a summary of cross-tabulations of DRS and NSS scores and four 
variables associated with social functioning in patients with schizophrenia: (1) patient reports 
having no confidant (O2a); (2) family reports feeling overwhelmed (O2b); (3) visit by a long-
standing relation (O6b); and (4) telephone with a social relation (O6c).  Chi-square analysis 
for each of the social functioning predictors was significant.  Specifically, for those who 
reported having no confidant, they also showed more depressive and/or negative symptoms 
than those who reported having a confidant.  Similarly, when the family reports feeling 
overwhelmed, the presence of depressive and/or depressive symptoms are also more 
prominent.   Although the visit by a social relation item was significant at the 0.08 level, no 
clear pattern across DRS and NSS scores are evinced.  When the patient did not have 
telephone contact with a social relation, negative symptoms only are higher than those who 




Table 19 displays a summary of cross-tabulations of DRS and NSS scores and four 
variables associated with social functioning in patients with a mood disorder.  Three social 
predictors are important: (1) patient reports having no confidant; (2) family reports feeling 
overwhelmed; and (3) telephone contact with a social rel tion.  When the patient reports 
having no confidant, the percentage of depressive and negative symptoms are much higher 
than those who have a confidant (49.9% vs. 37.5%).  When the family reports feeling 
overwhelmed, depressive and/or negative symptoms are also higher than when the family did 
not report feeling overwhelmed.  When the patient did not have telephone contact with a 
social relation, negative symptoms only and both depressive and negative symptoms are 
higher than when others who had telephone contact with a social relation.  
Table 20 displays a summary of cross-tabulations of DRS and NSS scores and four 
variables associated with social functioning in patients with both schizophrenia and a mood 
disorder.  Only one social predictor was important here: family reports feeling overwhelmed 
(p=0.03).  As such, DRS and NSS scores are related to the family reports feeling 
overwhelmed item.  When the family is overwhelmed, the patient shows much more 
depressive and negative symptoms.   
Table 21 displays a summary of cross-tabulations of DRS and NSS scores and four 
variables associated with social functioning in patients with neither schizophrenia nor a mood 
disorder.  Three variables are predictors of DRS and NSS scores:  (1) patient reports having 
no confidant; (2) family reports feeling overwhelmed; and (3) visit by a social relation.  
When the patient reports having no confidant, negative symptoms only and depressive and 




family reports feeling overwhelmed, the percentage of both depressive and negative 
symptoms are much higher than when the item was not endorsed (31.5% vs. 22.9%).  Visit 
by a social relation was also related to DRS and NSS scores. Negative symptoms only and 
both depressive and negative symptoms are higher whn the patient had not been visited by a 
social relation.   
5.2.6   Treatment modalities (L3a-d) and adherence with treatment (L5) 
 Table 22 shows DRS and NSS scores at Time 1, treatment modalities, and adherence 
with treatment by the diagnosis of schizophrenia.  As seen, treatment modalities are 
associated with DRS and NSS scores, where adherence to treatment was not.  If any of the 
following treatments: individual therapy, group therapy, family therapy, and self-help group 
were received, then treatment modality is scored as a “Yes”.  Although treatment modalities 
are associated with DRS and NSS scores, there does not appear to be a positive benefit of 
treatment (i.e., those who received treatment had more depressive and negative symptoms 
than those who did not receive treatment).  Perhaps, the depressive and negative symptoms 
are more severe for those who receive therapy; therefore, more depressive and negative 
symptoms are seen.   
Table 23 shows DRS and NSS scores at Time 1, treatment odalities, and adherence 
with treatment by the diagnosis of a mood disorder.  As seen, treatment modalities are 
associated with DRS and NSS scores, where adherence to treatment was not.  For those who 
received treatment, the negative symptoms only and depressive symptoms only scores are 




Table 24 shows DRS and NSS scores at Time 1, treatment odalities, and adherence 
with treatment by the diagnosis of schizophrenia and  mood disorder.  As seen, treatment 
modalities are associated with DRS and NSS scores, where adherence to treatment was not.  
For those who received treatment, the negative sympto s only and depressive symptoms 
only scores are lower than those who did not receiv treatment.   
Table 25 shows DRS and NSS scores at Time 1, treatment odalities, and adherence 
with treatment by the diagnosis of neither schizophrenia nor mood disorder.  As seen, 
treatment modalities and adherence with treatment ar  both associated with DRS and NSS 
scores.  For those who were adherent to treatment, their depressive and/or negative symptom 
scores were lower than those who were not adherent with he treatment.  Once again, 
although chi-square analysis showed therapy to be related to DRS and NSS scores, there does 
not appear to be a positive benefit (i.e., more depressive and negative symptom scores are 
seen when the patient received therapy).  
5.2.7 Medication refusal (K2) and antipsychotic med ications 
 Medication refusal is associated with DRS and NSS scores for those diagnosed with 
schizophrenia (See Table 26).  Those who refused their medications had more depressive 
and/or negative symptoms than those who did not.  Medication and DRS and NSS scores 
were not significant for patients diagnosed with a mood disorder (See Table 27).  In patients 
who were diagnosed with both schizophrenia and a mood disorder, DRS and NSS scores 
were associated with medication refusal. Specifically, those who refused their medications 
presented with more depressive symptoms only and both negative and depressive symptoms 




schizophrenia nor a mood disorder, chi-square analysis also showed an association between 
DRS and NSS scores and medication refusal. Specifically, those who refused their 
medications showed more depressive symptoms only than those who did not (See Table 29).  
 Atypical antipsychotic medication was also cross tabulated with DRS and NSS scores 
across the four diagnostic groups. It is important o note that all patients who were given an 
atypical antipsychotic medication were also already on a typical antipsychotic medication. In 
contrast, those who were on a typical antipsychotic medication had not necessarily been 
prescribed an atypical antipsychotic medication.  The results showed that atypical 
antipsychotic medication was only associated with DRS and NSS scores at Time 1 in 
individuals diagnosed with schizophrenia (p<.0001).  Table 26 summarizes the results. In 
contrast, typical antipsychotic medications were not associated with DRS and NSS scores for 
any of the four diagnostic groups (See Table 26-29).  When both atypical and typical 
medications are given to patients with schizophrenia, there appeared to be an association 
between DRS and NSS scores and both antipsychotic medications.   
5.2.8 Insight (B2) 
 Table 30 shows DRS and NSS scores at Time 1 cross-tabulated with insight by the 
four diagnostic groups. Insight was associated withDRS and NSS scores for three diagnostic 
groups: schizophrenia, mood disorder, and neither schizophrenia nor a mood disorder.  In the 
schizophrenia group, for those who had full insight, 59.6% had no depressive or negative 
symptoms, compared to 32.6% in the limited insight group, and 35.2% in the no insight 
group. Similarly, for those who had full insight, 16.2% had both depressive and negative 




group.  Insight appears to be related to less depressiv  and negative symptoms, and lack of 
insight appears to be related to more depressive and negative symptoms.   
 In the mood disorders group, for those who had full insight into their illness, 
approximately one-third falls into the no depressive and no negative symptoms category; 
however, one-third also falls into the depressive and negative symptoms category.  For those 
with limited insight, the majority belongs to the dpressive and negative symptoms category. 
A similar pattern is evinced in the no insight group.  
 For those who were diagnosed with neither schizophrenia nor a mood disorder and 
had full insight, the majority falls into the no depr ssive and negative symptoms category.  In 
those with limited insight, one-third of whom are in the no depressive and negative symptom 
category, and the other one-third have both depressive and negative symptoms. Interestingly, 
in those with no insight, one-third showed no depressive or negative symptoms, but one-third 
also shows negative symptoms only.   
5.2.9 Cognitive Performance Scale (CPS=0-3) 
 The sample comprised of individuals who had a CPS score of less than 3, which 
excluded individuals who have moderate to severe cognitive function.  Cross-tabulations 
were done for CPS of less than 3 and DRS and NSS scores for each of the four diagnostic 
groups (See Table 31).  Chi-square analysis showed that CPS and NSS and DRS scores were 
associated for three groups: schizophrenia, mood disor er, and neither schizophrenia nor a 
mood disorder. In the schizophrenia group, for those who have no cognitive difficulties 
(CPS=0), 42.4% have no depressive and no negative symptoms. For those who have mild 




25.7% have both depressive and negative symptoms. For those who have a CPS value of 2, 
33.3% have both depressive and negative symptoms. For those who have a CPS value of 3, 
31.9% have both depressive and negative symptoms. Therefore, as cognitive function 
worsens, depressive and negative symptoms also increase.   
 In the mood disorders group, regardless of CPS score, the majority of people either 
fall into the no depressive nor negative symptoms category or both depressive and negative 
symptoms category.  
 In patients who were diagnosed with neither schizophrenia nor a mood disorder, those 
who have a CPS value of 0, 1, or 2, the majority either fell into the no depressive nor 
negative symptoms category or both depressive and negative symptoms category. However, 
those who had a CPS score of 3, the majority fell into the no depressive and no negative 
symptoms category, but 26.6% also fell into the negative symptoms only category.  
Research Question 2: To what extent do depressive and negative symptoms 
improve over time among individuals with schizophrenia? More specifically, what 
variables predict an improvement in these symptoms? 
5. 3 Bivariate analyses 
 Chi-square analysis was carried out to determine the variables that predicted an 
improvement in DRS and NSS scores from Time 1 to Time 2 in each of the four diagnostic 
groups: schizophrenia, mood disorder, both schizophrenia and mood disorder, and neither 
schizophrenia nor mood disorder. A total of 12 variables were tested to see if they predicted 




diagnosis, one demographic variable (age), two mental health service history items (number 
of recent psychiatric admissions, and age at first ho pitalization), one social support variable 
(patient reports having no confidant), four patient characteristic items (current in-patient 
status, discharge readiness, insight, and current patient type), four medication-related items 
(medication refusal, atypical antipsychotic medication, typical antipsychotic medication, and 
both atypical and typical antipsychotic medications), and one treatment item (therapy).  A 
cut-off probability level of 0.10 was used to asses significance between the independent and 
dependent variables.  Bivariate analyses were also done to determine variables to be included 
in multivariate analyses.   
5.3.1    Diagnosis 
 Bivariate analysis was used to test the relationship between each diagnostic group and 
improvement in DRS and NSS scores from Time 1 to Time 2.  For those with a diagnosis of 
schizophrenia, 58.1% had an improvement in DRS and NSS scores, compared to 65% for 
mood disorders, 68.1% for both schizophrenia and mood disorders, and 62% for neither 
schizophrenia nor mood disorders. However, diagnosis was not related to improvement of 
DRS and NSS scores (p=0.2379) (See Table 32). 
5.3.2 Demographic   
 Age (14-25 or 25+) was not related to improvement of DRS and NSS scores from 




5.3.3 Mental health service history 
Number of recent psychiatric admissions (DD1) was associated with improvement of 
DRS and NSS scores only for the mood disorders group (p=0.09).  For those who had zero 
recent psychiatric admissions, 69.5% had an improvement in DRS and NSS scores. For those 
who had one or two recent psychiatric admissions, 61.4% had an improvement in DRS and 
NSS scores.  For those who had three or more recent psychiatric admissions, 57.5% had an 
improvement in DRS and NSS scores.  Therefore, as the number of recent psychiatric 
admissions increase, improvement of DRS and NSS score  appear to decrease (See Table 
34).  
Age at first hospitalization (DD6) was associated with improvement of DRS and NSS 
scores for those with schizophrenia, and both schizop renia and mood disorders.  For those 
diagnosed with schizophrenia, a higher percentage of individuals in the 15-24 and 25-44 age 
groups had improvements in DRS and NSS scores (58.1% and 71.1%), compared to 33.3% in 
the 0-14 age group, 37.5% in the 45-54 age group, and 16.7% in the 65+ age group.  Thus, 
the most improvement in individuals with schizophrenia is seen in the young and middle 
adulthood groups. For those with a comorbid diagnosis f schizophrenia and a mood 
disorder, improvement of DRS and NSS scores are also evident in the age groups, but since 
the sample size within this group is small, any trends are noted with caution (See Table 35).  
5.3.4 Social support 
The patient reports feeling overwhelmed (O2a) item was not related to an improvement 




5.3.5 Patient characteristics 
Current in-patient status (A3) was related to an improvement of DRS and NSS scores for 
the schizophrenia group only (p=0.004). In those who had a voluntary admission, 71.1% had 
improvements in DRS and NSS scores. For those who had an involuntary admission, only 
51.8% had an improvement in DRS and NSS scores. Therefor , improvement of DRS and 
NSS scores appear to be related to whether the patint was admitted to the hospital on a 
voluntary basis or not (See Table 37). 
Current in-patient type (Q5) was related to an improvement of DRS and NSS scores for 
the mood disorders group only (p=0.10). The majority of acute and longer-term patients both 
had improvements in DRS and NSS scores (64.2% and 76.6% respectively). The sample size 
in the geriatric psychiatry and forensic groups are too small to warrant any generalizations 
(See Table 38).   
Insight (B2) was unrelated to improvement of DRS and NSS scores for the four 
diagnostic groups (See Table 39).  
Discharge readiness (P2b) was also not associated wi h an improvement of DRS and NSS 
scores for the four diagnostic groups (See Table 40). 
5.3.6 Medication-related items 
Medication refusal (K2) was associated with an improvement in DRS and NSS scores for 
the schizophrenia group only (p=0.06). For those who did not refuse their medications, 
61.3% had an improvement in depressive and negative symptoms. For those who did refuse 




Therefore, medication refusal appears to be related to improvement in DRS and NSS scores 
(See Table 41). 
Atypical antipsychotic medications are related to improvement in DRS and NSS scores 
(p<.0001) in those diagnosed with schizophrenia.  Atypical antipsychotic medications are 
also related to improvement in DRS and NSS scores (p<0.006) in those diagnosed with both 
schizophrenia and a mood disorder.  Atypical antipsychotic medications appear to be related 
to improvements in depressive and negative symptoms f r those with schizophrenia or 
comorbid schizophrenia and mood disorder (See Table 42).  
Typical antipsychotic medications are also related to an improvement in DRS and NSS 
scores, but to a lesser extent than atypical antipsychotic medications (p=0.05) in those 
diagnosed with schizophrenia (See Table 43). 
Both typical and atypical antipsychotic medications are related to an improvement in 
DRS and NSS scores for those with schizophrenia (p=0.007), both schizophrenia and mood 
disorder (p=0.08), and neither schizophrenia nor mood disorder (p=0.01). For those with 
schizophrenia who were treated with both atypical and typical antipsychotic medications, 
70.0% of these individuals had an improvement in depressive and negative symptoms.  The 
sample size for the latter two groups was relatively small, so the significance of the findings 
is questioned (See Table 44).  
5.3.7 Therapy 
Therapy (individual therapy, group therapy, family therapy, or self-help group) was 
associated with an improvement in DRS and NSS score f  the schizophrenia group only 




depressive and negative symptoms. For those who did not received any therapy, only 47.6% 
showed improvements in depressive and negative symptoms.  Thus, therapy appears to be 
related to an improvement in depressive and negative symptoms (See Table 45). 
5.4 Multivariate analyses 
 From the results of the bivariate analyses, nine variables emerged as being 
significantly related to improvement of depressive and negative symptoms in any of the four 
diagnostic groups: number of recent psychiatric admissions (DD1), age at first hospitalization 
(DD6), current in-patient status (A3), therapy (L3a-d), medication refusal (K2), current 
patient type (Q5), atypical antipsychotic medication, typical antipsychotic medication, and 
both atypical and typical antipsychotic medication.  When all of these variables were entered 
into a stepwise logistic model, the following emerged as being important predictors of 
improvement in DRS and NSS scores: (1) the diagnosis of schizophrenia; (2) number of 
recent psychiatric admissions; and (3) atypical antipsychotic medications.  Atypical 
antipsychotic medications were positively related to improvement of DRS and NSS scores. 
Individuals with schizophrenia were less likely to improve.  The diagnosis of schizophrenia 
was inversely related to improvement of DRS and NSS scores.  Number of recent psychiatric 
admissions was also inversely related to DRS and NSS scores: a lower number of recent 
psychiatric admissions were related to a greater imp ovement in DRS and NSS scores.  When 
the same nine variables were entered into a logistic regression model, the same three 
variables of fewer recent psychiatric admissions, receiving atypical antipsychotic 
medications and not having a diagnosis of schizophrenia were related to improvement in 




 Another logistic model was conducted using a manual method.  All variables that 
were significant at the bivariate level were left in the model, they were then subsequently 
eliminated one by one until an optimal model was derived.  For example, variables that were 
definitely insignificant (p=0.80) were eliminated first, then others were continuously 
eliminated in a similar manner. Variables that were close to significance were then entered 
into the model. As such, a manual method of variable elimination and addition was employed 
to obtain a model for improvement of DRS and NSS scores.  The following predictors were 
obtained: (1) schizophrenia; (2) number of recent psychiatric admissions (DD1); (3) insight 
(B2); (4) patient reports having no confidant; and (5) both typical and atypical antipsychotic 
medications (See Table 46).  According to this model, those who were diagnosed with 
schizophrenia compared to the other three diagnostic groups were less likely to show 
improvements in depressive and negative symptoms over time. Recent psychiatric 
admissions were also related to improvement in these symptoms; specifically, those who had 
more psychiatric admissions were less likely to improve. In addition, insight into one’s 
condition was related to an improvement in DRS and NSS scores over time. Last, both 
atypical and typical antipsychotic medications were found to be associated with the 
improvement of depressive and negative symptom score  from Time 1 to Time 2.  However, 
the item, patient reports having no confidant, failed to reach statistical significance.  The 
Hosmer-Lemeshow test, which is a goodness-of-fit test, was employed to test whether the 
model yielded a good fit (x2 = 9.61; df = 8, p = 0.29).  
 A final logistic regression model was undertaken, which was similar to the previous 




analyses, four factors were significantly associated with an improvement in depressive and 
negative symptoms over time: (1) no diagnosis of schizophrenia; (2) fewer number of recent 
psychiatric admissions; (3) insight into one’s illness; and (4) receiving both atypical and 
typical antipsychotic medications, in combination.  According to the Hosmer-Lemeshow’s 



















This study examined patients’ characteristics; specifically the factors associated with 
depressive and negative symptoms at one point in time (Time 1) and the improvement of 
these symptoms over time (from Time 1 to Time 2) in individuals with schizophrenia, as well 
as three other psychiatric groups: mood disorders, both schizophrenia and mood disorders, 
and neither schizophrenia nor a mood disorder.  Numerous studies have been undertaken on 
the predictors of poor outcome in patients with schizophrenia; the presence of depressive 
symptoms has been associated with poor outcome. However, less research has been done to 
identify those factors that are associated with depressive and negative symptoms across 
different psychiatric groups.  As such, the first di cussion will be geared towards comparing 
the different factors associated with DRS and NSS scores for the four psychiatric groups.   
Secondly, given that depressive symptoms are common in schizophrenia, it is insufficient 
to simply measure the prevalence of depressive sympto s in this population. Instead, we 
need to address the question of whether these symptoms improve over time and identify the 
variables that are related to improvement. Next, a section on limitations, implications, and 
contributions of this research will be discussed, followed by suggestions for future research 




6.1 Comparison of factors associated with depressive and negative symptoms 
across major psychiatric groups 
6.1.1 Demographic factors 
 
 This is one of the first studies to consider such a broad range of variables (e.g., social, 
clinical, and demographic) based upon a comprehensiv  and standardized instrument for  
psychiatry.  The results from the comparison across the four psychiatric groups revealed 
many differences in patient characteristics. For example, in terms of gender and age group, 
these demographic variables were related to DRS and NSS scores at Time 1 for those with 
(1) schizophrenia, and (2) mood disorders. However, only gender was associated with DRS 
and NSS scores at Time 1 for the comorbid (both schizop renia and mood disorder)and 
neither group (neither schizophrenia nor mood disorer).  This finding is consistent with the 
current literature and provides further support thamood disorders appear to be more 
common in females and the suggested age group most likely to be affected is in mid-
adulthood, whereas schizophrenia is more prevalent in younger males in psychiatric settings 
(Escamilia, 2001; Glick et al., 2001; Siris, 2000).  Although comorbid schizophrenia and 
mood disorder is a common diagnosis, mood symptoms are often believed to be a 
manifestation of schizophrenia.  Theories such as the Bipolar Continuum Theory support the 
idea that mood disorders and schizophrenia are on the same continuum of disorders, but they 
only differ by symptom severity (Möller, 2003). Therefore, it is not surprising that variables 
associated with DRS and NSS in schizophrenia and mood disorders are also important in the 




6.1.2 Psychiatric history factors 
Kay and Murrill (1990) identified several clinical predictors for improved outcomes in 
individuals with schizophrenia.  For example, an ill ess duration of less than two years, and a 
psychotic psychiatric profile was found to be relatd with a better outcome.  In the present 
study, four additional psychiatric history variables (age of first hospitalization, number of 
recent psychiatric admissions, current patient type, and current inpatient status) were tested 
for association with depressive and negative symptos at Time 1 across the four psychiatric 
groups.  Similarly, it was found that age of first hospitalization was associated with 
depressive and negative symptoms in individuals with schizophrenia.  Specifically, 
individuals with an early onset had higher levels of depressive and negative symptoms.  This 
study also found number of recent psychiatric admissions to be related to DRS and NSS 
scores for three groups: schizophrenia, mood disorders, and neither.  Specifically, higher 
numbers of recent psychiatric admissions were related to increased levels of depressive and 
negative symptoms.   
The findings on current-inpatient status also adds to the literature because there is 
minimal research on the association between depressive ymptoms and patient status (i.e., 
whether a patient was admitted on a voluntary or involuntary basis).  To compare, individuals 
with schizophrenia were more likely to be admitted on an involuntary basis than those with a 
mood disorder.  Negative symptoms and insight have been reported to be correlated in 
patients with schizophrenia (Harvey et al., 2006), which helps to explain why patients with 
schizophrenia are more likely to be admitted to a psychiatric facility on an involuntary basis.  




some new light with respect to its association with depressive and negative symptoms.  
Specifically, acute patients were less likely to shw improvements in depressive and negative 
symptoms over time. 
6.1.3 Social functioning factors 
 
Social support as a resource for coping and adaptation is an important resource for 
individuals with schizophrenia (Saunders, 2003). Social support is believed to serve a 
protective factor in helping individuals with schizophrenia cope with stressors (Buchanan, 
1995).  According to the Stress Vulnerability Model, depression is believed to be a 
significant stressor to trigger a psychotic episode.  As such, social support is important to 
help individuals cope with their illness.  The research findings from the analyses in this study 
illustrate that social support is important in minimizing depressive symptoms over time.   
6.1.4 Improvement of depressive and negative sympto ms over time 
From the results of the bivariate analysis, it was found that depressive and negative 
symptoms do improve from Time 1 to Time 2 in those with schizophrenia.  This is important 
because treatment can be targeted to further minimize the depressive and negative symptoms 
over time.  The majority of existing research has identified depressive symptoms as a factor 
related to poor outcome in individuals with schizophrenia.  Since depressive and negative 
symptoms are so prevalent in individuals with schizophrenia, the aim should be on treating 
these symptoms in order to increase the quality of life in this population.  To recapitulate, of 




Time 1, 50.4% of them had neither of the symptoms at Time 2.  This is a remarkable 
improvement when half of these individuals experienced decreased symptomatology in 
depressive and negative symptoms from Time 1 to Time 2.  Moreover, additional analyses 
were done to see what factors predicted an improvement in depressive and negative 
symptoms.  The results from the logistic regression m del showed that four variables best 
predicted an improvement in depressive and negative symptoms. They include: (1) not 
having a diagnosis of schizophrenia; (2) insight into mental health; (3) lower number of 
recent psychiatric admission; and (4) receiving both typical and atypical antipsychotic 
medications in combination.   
Over the past two decades, there has been considerable research on atypical and typical 
antipsychotic medication use and their association with depressive symptoms.  More 
recently, atypical antipsychotic medications have received more attention because they are 
associated with fewer side effects. However, the majority of these studies have been cross-
sectional in nature (De Nayer, 2003; Möller, 2004).  In the longitudinal analyses of the 
present study, it was evident that there was an improved side effect profile (i.e., less 
depressive and negative symptoms over time) in those individuals who were treated with 
both typical and atypical antipsychotic medications.  Perhaps, both types of medications are 
useful in treating the depressive and negative sympto s over time.   
6.1.5 Implications of findings on improvement rates  for benchmarking purposes 
An important finding of this study is that depressive and negative symptoms do 




it is important to consider risk adjustment in order to make any fair comparisons across 
facilities.  Risk-adjustment allows us to provide a reliable "benchmark" for evaluating 
performance across a broad range of clinically relevant populations.  Risk adjustment 
requires defining specific outcomes, and measuring each risk factor accordingly.  For 
example, in this study, it would have been beneficial to control for severity of schizophrenia. 
As such, severity of illness is a form of risk adjustment.  Schizophrenia is a broad diagnosis 
that includes not only symptoms of psychosis and negative symptoms; individuals can also 
have catatonic symptoms, as well as poverty of speech problems.  The improvement of 
depressive and negative symptoms over time is better understood if severity of illness was 
risk adjusted, and valid comparisons across different psychiatric facilities can be made.  
Similarly, there may be an association between number of recent psychiatric admissions and 
severity of illness.  
6.2 Limitations 
 Despite the benefits of a large sample size and data collection based upon a 
standardized and comprehensive instrument, which provided information on a range of 
demographic, psychiatric, clinical, and social variables, nonetheless limitations still exist.  
 First, these findings are based upon an analysis of secondary data. As such, there may 
be some inherent constraints, for example, there is r stricted use of the variables and scales in 
the instrument.  For example, there is no information on type of medications that patients 
have tried before being placed on the current medication. Moreover, there is no information 




has had enough time to reach therapeutic effectiveness.  Although assessors were required to 
document the type and dosages of each medication the patient is currently taking, it does not 
provide any information on why the medication was administered.   
Second, in the DRS, depressive symptoms are only coded if they are present within 
the last 3 days. However, according to the DSM-IV, a diagnosis of major depressive disorder 
is given only if symptoms are present within a 2-week period.  On a similar note, in the RAI-
MH, the diagnosis information is based on a provisinal diagnosis. Provisional diagnoses are 
not based on a systematic diagnostic tool; as such, there may be errors in the diagnoses.   
Third, many complications arise when conducting analyses around medications.  Any 
significant finding can be confounded by dosages, drug interactions, or duration of the drug.  
Although, the present study attempts to study the relationship between antipsychotic use and 
depressive symptoms longitudinally, the results should be viewed with these limitations in 
mind 
Fourth, the four categories of DRS and NSS scores were grouped for the purpose of 
studying how these symptoms compared across different diagnoses; this modeling attempts 
to address both the depressive and negative symptoms of schizophrenia, but this 
conceptualization has not been validated, so the results are suggestive and preliminary. 
Fifth, depressive and negative symptoms were measurd in the present study, but the 
literature shows that major depression is a comorbid syndrome in schizophrenia.  The RAI-
MH categorizes major depression under the mood disorders group; so unfortunately, the 




study the schizoaffective disorder group (a diagnosis between bipolar disorder and 
schizophrenia).  
Sixth, although an improvement in depressive and negative symptoms was found, it is 
important to note that there were only two assessment p riods (i.e., Time 1 and Time 2).  A 
Time 2 assessment is done when a patient is discharged, at 3-month re-assessment, or when 
there is a change in patient status (e.g., a fall). Therefore, the Time 2 assessment is 
heterogeneous in that the purpose of the re-assessment is done for different reasons.  
However, given that we only have assessments at two points in time; the longitudinal nature 
of the data still provides us with some valuable information.   
6.3 Contribution 
Although there were some limitations to this study, there were also aspects that 
contributed to the current literature.  As previously noted, the Depression Rating Scale (DRS) 
is a standardized instrument for measuring depression, and has been validated against the 
Hamilton Depression Rating Scale, the Cornell Depression Rating Scale (Burrows et al., 
2000), and the Beck Depression Inventory (unpublished).  As such, this study attempts to 
consistently measure depressive symptoms within the four diagnostic groups.  After 
comparing the DRS with other standardized depression to ls, it was found that the DRS did 
not include items that measure the anhedonic featurs of depression (or negative symptoms 
of schizophrenia). As such, the Negative Symptom Scale from the RAI-MH was incorporated 
into our analyses in order to take into account the importance of anhedonic features of 
depression.  In addition, by grouping both the DRS and NSS subscales into four categories, it 




with schizophrenia, but also allows us to compare ac oss different diagnoses.  This is one of 
the first studies to measure depressive symptoms in this manner.   
 This study also controlled for the potential confounding effect of poor cognition on 
depressive and negative symptoms.  As such, the results of this study can be generalized to 
individuals with schizophrenia in psychiatric settings who have intact cognitive function.   
 The RAI-MH is a comprehensive instrument that allowed us to test for associations 
between many different factors (as independent variables) and DRS and NSS scores (as a 
dependent variable). Variables such as insight into o e’s mental health and fewer numbers of 
recent psychiatric admissions were shown to be related to depressive and negative symptoms; 
this adds to the current literature on predictors of depressive symptoms.   
The present study also attempts to study the improvement of DRS and NSS scores 
over time for those diagnosed with schizophrenia. The majority of studies in this area have 
taken the cross-sectional approach; as such, the longitudinal nature of this study will 
contribute significantly to the mixed findings in this area.   
This study also showed that both typical and atypical antipsychotic medications, in 
combination, are related to improvement of depressiv  and negative symptoms.  Although, 
specific atypical or typical antipsychotic medications were not associated with an 
improvement in DRS and NSS scores, it is still a step in the right direction to guide future 




6.4 Future Research 
 The focus of treatment was not discussed in this paper, primarily because there was 
insufficient information on the details of the therapy individuals had received. Any 
discussion of treatment strategies is incomplete wihout considering the type of intervention 
that was given to patients.   There is mixed findings concerning the addition of 
antidepressants for depressive symptoms in patients with schizophrenia. It would be 
interesting to see if there is a relationship betwen both atypical antipsychotic medications 
and antidepressants and improvement of depressive and negative symptoms.   
Depressive symptoms tend to be more prominent at life events or at the genetic 
predisposition end of the spectrum, so are associated with a more favourable outcome. In 
contrast, negative symptoms occur earlier in the life course, and therefore are associated with 
poor prognosis. Future research should study the prognostic effect of depressive and negative 
symptoms in those with schizophrenia.       
In some recent studies, depressive symptoms appear to be more related to positive 
symptoms than with the negative symptoms of schizophrenia. So whether depressive 
symptoms are a core component of schizophrenia or are merely the result of living with 
persistent and severe psychosis (i.e., post-psychotic depression) should be further 
investigated.    
6.5 Conclusion 
In our analysis, depressive and negative symptoms in ind viduals with schizophrenia 




and negative symptoms did not share the same pattern cross the four diagnostic groups, 
suggesting that these symptoms represent a different p ofile in each of the diagnostic groups.  
Moreover, depressive and negative symptoms did improve from admission to discharge in 
individuals with schizophrenia, and predictors of this improvement included the following 
variables: (1) not having a diagnosis of schizophrenia; (2) insight into mental health; (3) 
fewer number of recent psychiatric admissions; and (4) receiving both typical and atypical 
antipsychotic medications, in combination. Moreover, the results show that those who were 
given both types of medications were two times more likely to show improvements in 
depressive and negative symptoms over time.  
In conclusion, depressive and negative symptoms in schizophrenia need continuing 
systematic investigation, particularly in view of their relevance for clinical treatment and 

















Table 1. Demographics (age and sex), Depression Rat ing Scale (DRS), and Negative 
Symptom Scale (NSS) of sample (where Cognitive Perf ormance Scale ≤ 3), by the four 
diagnostic groups 
___________________________________________________________________ 
        All   
(n=3,269) 
        Mean (SD) 
___________________________________________________________________ 
Age  
 *Szp       43.7 (17.2)  
 Mood       46.6 (16.4)  
Both Szp and Mood     45.9 (17.4)  
Neither Szp nor Mood     49.4 (21.5)  
___________________________________________________________________ 
Sex (male)        % (n) 
 Szp       62.1 (363)   
 Mood       42.9 (664)  
Both Szp and Mood     47.2 (109)  
Neither Szp nor mood     52.5 (263) 
Depression Rating Scale (DRS 3+)1 
 Szp       39.2 (378) 
 Mood       55.8 (869) 
Both Szp and Mood     42.5 (99) 
Neither Szp nor mood     43.5 (219) 
Negative Symptom Scale (NSS 1+)2 
 Szp       49.7 (480) 
 Mood       54.8 (856) 
Both Szp and Mood     50.4 (118) 
Neither Szp nor mood     45.0 (227) 
___________________________________________________________________ 
*Szp = schizophrenia 
1 = DRS 3+ = presence of depressive symptoms 













Table 2. DRS and NSS scores by the four diagnostic groups 
      Diagnosis [% (n)] 
DRS_NSS   Szp*  Mood  Szp & Mood Neither Szp nor 
Mood 
____________________________________________________________________________ 
DRS 0-2 & NSS = 0  36.2 (349) 29.7 (464) 35.5 (83) 37.8 (191) 
DRS 0-2 & NSS ≥ 1  24.6 (237) 14.4 (225) 21.8 (51) 18.6 (94) 
DRS ≥ 3 & NSS = 0  14.1 (136) 15.5 (242) 14.1 (51) 17.2 (87) 
DRS ≥ 3 & NSS ≥ 1  25.2 (243) 40.4 (631) 28.6 (67) 26.3 (133) 
____________________________________________________________________________ 





Table 3. DRS and NSS scores at Time 1 and Time 2 by  diagnosis of no schizophrenia  
       DRS_NSS Time 2 
DRS_NSS Time 1  DRS 0-2 & NSS = 0 DRS 0-2 & NSS ≥ 1 DRS ≥ 3 & NSS = 0 DRS ≥ 3 & NSS ≥ 1  
___________________________________________________________________________________________ 
DRS 0-2 & NSS = 0  87.8 (165)  4.8 (9)   5.3 (10)   2.1 (4) 
DRS 0-2 & NSS ≥ 1  57.7 (75)  33.9 (44)  0.8 (1)   7.7 (10) 
DRS ≥ 3 & NSS = 0  55.2 (74)  1.5 (2)   36.6 (49)  6.7 (9) 


















Table 4. DRS and NSS scores at Time 1 and Time 2 by  diagnosis of schizophrenia  
       DRS_NSS Time 2 
DRS_NSS Time 1  DRS 0-2 & NSS = 0 DRS 0-2 & NSS ≥ 1 DRS ≥ 3 & NSS = 0 DRS ≥ 3 & NSS ≥ 1  
___________________________________________________________________________________________ 
DRS 0-2 & NSS = 0  86.4 (133)  7.8 (12)   3.9 (6)   2.0 (3) 
DRS 0-2 & NSS ≥ 1  51.8 (59)  36.8 (42)  2.6 (3)   8.8 (10)  
DRS ≥ 3 & NSS = 0  51.7 (47)  3.3 (3)   38.5 (35)  6.6 (6) 















Table 5. DRS and NSS scores at Time 1 cross-tabulat ed with demographic predictors, by diagnosis of sch izophrenia  
DRS and NSS scores at Time 1   Percentage (n)    p-value 
__________________________________________________________________________________ 
Gender (BB1)      Male   Female  
 DRS 0-2 & NSS = 0    37.8 (225) 33.3 (121)  *0.02 
DRS 0-2 & NSS ≥ 1    27.2 (162) 20.4 (74) 
 DRS ≥ 3 & NSS = 0    12.1 (72) 17.6 (64) 
 DRS ≥ 3 & NSS ≥ 1    23.0 (137) 28.7 (104) 
 
   
Age (BB2)      Early onset1 Adult onset2 
     
DRS 0-2 & NSS = 0    34.9 (51) 36.4 (290)  0.06 
 
DRS 0-2 & NSS ≥ 1    32.9 (48) 23.0 (183) 
  
DRS ≥ 3 & NSS = 0    12.3 (18) 14.6 (116) 
     
DRS ≥ 3 & NSS ≥ 1    19.9 (29) 26.0 (207) 
____________________________________________________________________________________ 
1 = Early onset = age le 25 
2 = Late onset = age ge 25 















Table 6. DRS and NSS scores at Time 1 cross-tabulat ed with demographic predictors, by diagnosis of moo d disorder 
DRS and NSS scores at Time 1   Percentage (n)    p-value 
__________________________________________________________________________________ 
Gender (BB1)      Male   Female  
  
DRS 0-2 & NSS = 0    32.1 (213) 27.8 (245)   *<.0001 
 
DRS 0-2 & NSS ≥ 1    18.8 (125) 11.0 (97) 
  
DRS ≥ 3 & NSS = 0    13.6 (90) 17.0 (150) 
     
DRS ≥ 3 & NSS ≥ 1    35.5 (236) 44.3 (391) 
 
   
Age (BB2)      Early onset1 Adult onset2 
     
DRS 0-2 & NSS = 0    38.6 (51) 28.9 (392)   *0.04 
  
DRS 0-2 & NSS ≥ 1    12.1 (16) 14.5 (197) 
  
DRS ≥ 3 & NSS = 0    18.2 (24) 15.3 (208) 
     
DRS ≥ 3 & NSS ≥ 1    31.1 (41) 41.3 (561) 
 
____________________________________________________________________________________ 
1 = Early onset = age le 25 
2 = Late onset = age ge 25 






Table 7. DRS and NSS scores at Time 1 cross-tabulat ed with demographic predictors, by diagnosis of sch izophrenia and 
mood  
 
DRS and NSS scores at Time 1   Percentage (n)    p-value 
__________________________________________________________________________________ 
Gender (BB1)      Male   Female  
  
DRS 0-2 & NSS = 0    41.3 (45) 30.3 (37)  *0.01 
 
DRS 0-2 & NSS ≥ 1    26.6 (29) 16.4 (20) 
  
DRS ≥ 3 & NSS = 0    11.9 (13) 16.4 (20) 
     
DRS ≥ 3 & NSS ≥ 1    20.2 (22) 36.9 (45) 
 
   
Age (BB2)      Early onset1 Adult onset2 
     
DRS 0-2 & NSS = 0    39.3 (11) 35.7 (71)  0.70 
  
DRS 0-2 & NSS ≥ 1    25.0 (7)  21.6 (43) 
  
DRS ≥ 3 & NSS = 0    7.1 (2)  15.6 (31) 
     
DRS ≥ 3 & NSS ≥ 1    28.6 (8)  27.1 (54) 
 
____________________________________________________________________________________ 
1 = Early onset = age le 25 
2 = Late onset = age ge 25 





Table 8. DRS and NSS scores at Time 1 cross-tabulat ed with demographic predictors, by diagnosis of nei ther schizophrenia 
nor mood  
 
DRS and NSS scores at Time 1   Percentage (n)    p-value 
__________________________________________________________________________________ 
Gender (BB1)      Male   Female  
  
DRS 0-2 & NSS = 0    35.1 (92) 40.1 (95)  *0.005 
 
DRS 0-2 & NSS ≥ 1    24.4 (64) 12.7 (30) 
  
DRS ≥ 3 & NSS = 0    14.5 (38) 20.7 (49)  
     
DRS ≥ 3 & NSS ≥ 1    26.0 (68) 26.6 (63) 
 
   
Age (BB2)      Early onset1 Adult onset2 
     
DRS 0-2 & NSS = 0    43.3 (26) 37.8 (151)  0.31 
    
DRS 0-2 & NSS ≥ 1    13.3 (8)  19.6 (78)    
  
DRS ≥ 3 & NSS = 0    11.7 (7)  17.8 (71) 
     
DRS ≥ 3 & NSS ≥ 1    31.7 (19) 24.8 (99)  
 
____________________________________________________________________________________ 
1 = Early onset = age le 25 
2 = Late onset = age ge 25 





Table 9. DRS and NSS scores at Time 1 cross-tabulat ed with mental health service history, by diagnosis  of schizophrenia  
 DRS and NSS scores at Time 1    Percentage (n)      p-value 
__________________________________________________________________________________________________ 
Number of recent psychiatric admissions (DD1)  01  12  23        
  
DRS 0-2 & NSS = 0     36.0 (130) 38.4 (154) 32.0 (65)  *0.04 
 
DRS 0-2 & NSS ≥ 1     23.3 (84) 26.7 (107) 22.7 (46) 
  
DRS ≥ 3 & NSS = 0     16.9 (61) 9.7 (39)  17.7 (36)  
     
DRS ≥ 3 & NSS ≥ 1     23.8 (86) 25.2 (101) 27.6 (56) 
 
Age at first hospitalization (DD6)  0-14  15-24  25-44  45-54  65+ 
  
DRS 0-2 & NSS = 0   8.5 (28)  49.7 (164) 30.3 (100) 7.0 (23)  4.6 (15)    0.06 
  
DRS 0-2 & NSS ≥ 1   4.4 (10)  52.9 (119) 33.8 (76) 7.6 (17)  1.3 (3) 
 
DRS ≥ 3 & NSS = 0   10.3 (13) 39.7 (50) 38.9 (49) 18.2 (1 ) 6.9 (2) 
     
DRS ≥ 3 & NSS ≥ 1   16.4 (10) 25.0 (111) 27.4 (85) 21.2(14) 31.0 (9 ) 
__________________________________________________________________________________________________ 
*Indicates significance at the p < .05 value 
1 = no recent psychiatric admission 
2 = 1-2 recent psychiatric admission 







Table 10. DRS and NSS scores at Time 1 cross-tabula ted with mental health service history, by diagnosi s of mood disorder  
 
 DRS and NSS scores at Time 1    Percentage (n)      p-value 
__________________________________________________________________________________________________ 
Number of recent psychiatric admissions (DD1)  01  12  23        
  
DRS 0-2 & NSS = 0     28.3 (219) 33.5 (181) 25.8 (64)   0.09 
 
DRS 0-2 & NSS ≥ 1     14.4 (111) 15.3 (83) 12.5 (31) 
  
DRS ≥ 3 & NSS = 0     16.0 (124) 12.9 (70) 19.4 (48) 
     
DRS ≥ 3 & NSS ≥ 1     41.3 (319) 38.3 (207) 42.3 (105) 
 
Age at first hospitalization (DD6)  0-14  15-24  25-44  45-54  65+ 
  
DRS 0-2 & NSS = 0   7.6 (30)  27.0 (107) 39.4 (156) 29.8 (88) 3.8 (15)  0.17 
  
DRS 0-2 & NSS ≥ 1   7.3 (15)  25.2 (52) 39.3 (81) 22.8 (47) 5.3 (11) 
 
DRS ≥ 3 & NSS = 0   10.2 (22) 25.6 (55) 45.1 (97) 14.9 (32) 4.2 (9) 
     
DRS ≥ 3 & NSS ≥ 1   8.4 (48)  20.1 (115) 43.1 (247) 22.3 (128) 6.1 (35) 
__________________________________________________________________________________________________ 
1 = no recent psychiatric admission 
2 = 1-2 recent psychiatric admission 







Table 11. DRS and NSS scores at Time 1 cross-tabula ted with mental health service history, by diagnosi s of schizophrenia 
and mood disorder 
 
 DRS and NSS scores at Time 1    Percentage (n)      p-value 
__________________________________________________________________________________________________ 
Number of recent psychiatric admissions (DD1)  01  12  23        
  
DRS 0-2 & NSS = 0     35.0 (28) 33.7 (32) 39.0 (23)   0.70 
 
DRS 0-2 & NSS ≥ 1     17.5 (14) 25.3 (24) 22.0 (13) 
  
DRS ≥ 3 & NSS = 0     17.5 (14) 14.7 (14) 8.5 (5) 
     
DRS ≥ 3 & NSS ≥ 1     17.5 (24) 26.3 (25)  30.5 (18)   
 
Age at first hospitalization (DD6)  0-14  15-24  25-44  45-54  65+ 
  
DRS 0-2 & NSS = 0   4.0 (3)  44.0 (33) 34.7 (26) 16.0 (12) 1.3 (1)  0.37 
  
DRS 0-2 & NSS ≥ 1   0.0 (0)  53.0 (26) 36.7 (18) 8.2 (4)  2.0 (1) 
 
DRS ≥ 3 & NSS = 0   9.7 (3)  29.0 (9)  51.6 (16) 9.7 (3)  0.0 (0) 
     
DRS ≥ 3 & NSS ≥ 1   6.3 (4)  32.8 (21) 45.3 (29) 14.1 (9)  1.6 (1) 
__________________________________________________________________________________________________ 
1 = no recent psychiatric admission 
2 = 1-2 recent psychiatric admission 






Table 12. DRS and NSS scores at Time 1 cross-tabula ted with mental health service history, by diagnosi s of neither 
schizophrenia nor mood disorder 
 
 DRS and NSS scores at Time 1    Percentage (n)       p-value 
_______________________________________________________________________________________________________ 
Number of recent psychiatric admissions (DD1)  01  12  23        
  
DRS 0-2 & NSS = 0     39.7 (118) 41.4 (60) 19.7 (12)   *0.03 
 
DRS 0-2 & NSS ≥ 1     17.2 (51)  16.6 (24) 31.2 (19)   
  
DRS ≥ 3 & NSS = 0     18.2 (54) 15.9 (23) 14.8 (9) 
     
DRS ≥ 3 & NSS ≥ 1     24.9 (74) 26.2 (38) 34.4 (21)  
 
Age at first hospitalization (DD6)  0-14  15-24  25-44  45-54  65+ 
 DRS 0-2 & NSS = 0   9.9 (14)  26.1 (37) 23.9 (34) 46.8 (29) 19.7 (28) *0.02 
  
DRS 0-2 & NSS ≥ 1   12.0 (9)  29.3 (22) 29.3 (22) 10.7 (8)  18.7 (14) 
 
DRS ≥ 3 & NSS = 0   7.5 (5)  35.8 (24) 31.3 (21) 10.5 (7)  14.9 (10) 
     
DRS ≥ 3 & NSS ≥ 1   7.0 (8)  26.3 (30) 43.9 (50) 15.8 (18) 7.0 (8) 
______________________________________________________________________________________________________ 
*Indicates significance at the p < .05 value 
1 = no recent psychiatric admission 
2 = 1-2 recent psychiatric admission 







Table 13. DRS and NSS scores at Time 1 cross-tabula ted with current inpatient status (A3), by diagnosi s of schizophrenia  
 
 DRS and NSS scores at Time 1   Percentage (n)    p-value 
__________________________________________________________________________________ 
       Involuntary Voluntary  
  
DRS 0-2 & NSS = 0    46.4 (160) 53.6 (185)  *0.004 
 
DRS 0-2 & NSS ≥ 1    55.9 (132) 44.1 (104) 
  
DRS ≥ 3 & NSS = 0    64.0 (87) 36.0 (49)  
     
DRS ≥ 3 & NSS ≥ 1    51.9 (126) 48.2 (117) 
__________________________________________________________________________________   






















Table 14. DRS and NSS scores at Time 1 cross-tabula ted with current inpatient status (A3), by diagnosi s of mood disorder  
 
 DRS and NSS scores at Time 1   Percentage (n)    p-value 
__________________________________________________________________________________ 
       Involuntary Voluntary  
  
DRS 0-2 & NSS = 0    30.5 (141) 69.6 (322)  *0.02 
 
DRS 0-2 & NSS ≥ 1    41.3 (93) 58.7 (132)   
  
DRS ≥ 3 & NSS = 0    38.0 (92) 62.0 (150) 
     
DRS ≥ 3 & NSS ≥ 1    32.4 (204) 67.6 (425) 
__________________________________________________________________________________  



















Table 15. DRS and NSS scores at Time 1 cross-tabula ted with current inpatient status (A3), by diagnosi s schizophrenia and 
mood disorder 
 
 DRS and NSS scores at Time 1   Percentage (n)    p-value 
__________________________________________________________________________________ 
       Involuntary Voluntary  
  
DRS 0-2 & NSS = 0    38.6 (32) 61.5 (51)  0.16 
 
DRS 0-2 & NSS ≥ 1    40.0 (20) 60.0 (30) 
  
DRS ≥ 3 & NSS = 0    60.6 (20) 39.4 (13) 
     






















Table 16. DRS and NSS scores at Time 1 cross-tabula ted with current inpatient status (A3), by diagnosi s of neither 
schizophrenia nor mood 
 
 DRS and NSS scores at Time 1   Percentage (n)    p-value 
__________________________________________________________________________________ 
       Involuntary Voluntary  
  
DRS 0-2 & NSS = 0    29.3 (55) 70.7 (133)  0.16 
 
DRS 0-2 & NSS ≥ 1    36.3 (33) 63.7 (58) 
  
DRS ≥ 3 & NSS = 0    43.0 (37) 57.0 (49) 
     




















Table 17. DRS and NSS scores at Time 1 cross-tabula ted with current patient type (Q5), by the 4 diagno stic groups  
 
 DRS and NSS scores at Time 1    Percentage (n)      p-value 
_________________________________________________________________________________________________ 
Szp      Acute  Longer-term Geriatric psychiatry Forensic      
 DRS 0-2 & NSS = 0   29.8 (188) 47.6 (88) 51.8 (44)  44.6 (29) **<.0001   
DRS 0-2 & NSS ≥ 1   25.1 (158) 24.9 (46) 21.2 (18)  23.1 (15)  
 DRS ≥ 3 & NSS = 0   16.0 (101) 12.4 (23) 7.1 (6)   9.2 (6) 
 DRS ≥ 3 & NSS ≥ 1   29.1 (183) 15.1 (28) 20.0 (17)  23.1 (15) 
   
Mood 
 DRS 0-2 & NSS = 0   23.2 (278) 55.3 (145) 45.0 (36)  26.3 (5)  **<.0001   
DRS 0-2 & NSS ≥ 1   14.5 (174) 11.8 (31) 16.3 (13)  36.8 (7)   
 DRS ≥ 3 & NSS = 0   15.7 (188) 12.6 (33) 21.3 (17)  10.5 (2)   
 DRS ≥ 3 & NSS ≥ 1   46.6 (559) 20.2 (53) 17.5 (14)  26.3 (5)   
 
Both szp and mood 
 DRS 0-2 & NSS = 0   30.6 (45) 42.9 (18) 46.7 (14)  40.0 (6)  0.31  
DRS 0-2 & NSS ≥ 1   21.8 (32) 14.3 (6)  23.3 (7)   40.0 (6)   
 DRS ≥ 3 & NSS = 0   15.7 (23) 11.9 (5)  13.3 (4)   6.7 (1)   
 DRS ≥ 3 & NSS ≥ 1   32.0 (47) 31.0 (13) 16.7 (5)   13.3 (2)   
 
Neither szp nor mood 
DRS 0-2 & NSS = 0   24.1 (63) 55.8 (67) 51.0 (50)  50.0 (11) **<.0001  
DRS 0-2 & NSS ≥ 1   19.5 (51) 12.5 (15) 23.5 (23)  13.6 (3)   
 DRS ≥ 3 & NSS = 0   19.1 (50) 14.2 (17) 14.3 (14)  22.7 (5)   
 DRS ≥ 3 & NSS ≥ 1   37.4 (98) 17.5 (21) 11.2 (11)  13.6 (3)   
__________________________________________________________________________________________________________ 





Table 18. DRS and NSS scores at Time 1 cross-tabula ted with social functioning, by diagnosis of schizo phrenia  
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Patient reports having no confidant (O2a)   No   Yes        
 DRS 0-2 & NSS = 0     38.9 (304) 24.6 (45)  *0.002  
DRS 0-2 & NSS ≥ 1     23.4 (183) 29.5 (54)     
 DRS ≥ 3 & NSS = 0     14.1 (110) 29.5 (54)  
 DRS ≥ 3 & NSS ≥ 1     23.7 (185) 31.7 (58) 
 
Family reports feeling overwhelmed (O2b)    
 DRS 0-2 & NSS = 0     40.3 (255) 28.3 (94)  *0.003 
 DRS 0-2 & NSS ≥ 1     23.4 (148)  26.8 (89) 
DRS ≥ 3 & NSS = 0     12.6 (80) 16.9 (56) 
 DRS ≥ 3 & NSS ≥ 1     23.7 (150) 28.0 (93) 
 
Visit by social relation/family member (O6b) 
DRS 0-2 & NSS = 0     40.3 (94) 34.8 (255)  0.08 
 DRS 0-2 & NSS ≥ 1     26.2 (61) 24.0 (176) 
DRS ≥ 3 & NSS = 0     9.4 (22)  15.6 (114) 
 DRS ≥ 3 & NSS ≥ 1     24.0 (56) 25.6 (187) 
Telephone with social relation/family member (O6c)  
DRS 0-2 & NSS = 0     38.3 (82) 35.6 (267)  *0.02 
 DRS 0-2 & NSS ≥ 1     30.8 (66) 22.8 (171) 
DRS ≥ 3 & NSS = 0     11.2 (24) 14.9 (112) 
DRS ≥ 3 & NSS ≥ 1     19.6 (42) 26.8 (201) 
_________________________________________________________________________________________________ 





Table 19.  DRS and NSS scores at Time 1 cross-tabulated with s ocial functioning variables, by diagnosis of mood d isorder   
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Patient reports having no confidant (O2a)   No   Yes        
 DRS 0-2 & NSS = 0     32.2 (384) 21.6 (80)  *<.0001 
DRS 0-2 & NSS ≥ 1     14.1 (168) 15.4 (57)     
 DRS ≥ 3 & NSS = 0     16.2 (193) 13.2 (49)  
 DRS ≥ 3 & NSS ≥ 1     37.5 (446) 49.9 (185) 
 
Family reports feeling overwhelmed (O2b)    
 DRS 0-2 & NSS = 0     32.3 (303) 25.8 (161)  *0.05 
 DRS 0-2 & NSS ≥ 1     14.1 (132) 14.9 (93) 
DRS ≥ 3 & NSS = 0     14.7 (138) 16.7 (104) 
 DRS ≥ 3 & NSS ≥ 1     38.9 (365) 42.6 (266) 
 
Visit by social relation/family member (O6b) 
DRS 0-2 & NSS = 0     25.4 (48) 30.3 (416)  0.18 
 DRS 0-2 & NSS ≥ 1     13.8 (26) 14.5 (199) 
DRS ≥ 3 & NSS = 0     13.2 (25) 15.8 (217) 
 DRS ≥ 3 & NSS ≥ 1     47.6 (90) 39.4 (541) 
 
Telephone with social relation/family member (O6c)  
DRS 0-2 & NSS = 0     22.6 (31) 30.4 (433)  *0.04 
 DRS 0-2 & NSS ≥ 1     16.8 (23) 14.2 (202) 
DRS ≥ 3 & NSS = 0     11.0 (15) 15.9 (227 
DRS ≥ 3 & NSS ≥ 1     49.6 (68) 39.5 (563) 
_________________________________________________________________________________________________ 





Table 20.  DRS and NSS scores at Time 1 cross-tabulated with s ocial functioning variables, by diagnosis of schizo phrenia 
and mood disorder   
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Patient reports having no confidant (O2a)   No   Yes        
 DRS 0-2 & NSS = 0     38.8 (71) 23.5 (12)  0.15  
DRS 0-2 & NSS ≥ 1     21.9 (40) 21.6 (11)     
 DRS ≥ 3 & NSS = 0     13.7 (25) 15.7 (8) 
 DRS ≥ 3 & NSS ≥ 1     25.7 (47) 39.2 (20) 
 
Family reports feeling overwhelmed (O2b)    
 DRS 0-2 & NSS = 0     44.0 (59) 24.0 (24)  *0.03  
 DRS 0-2 & NSS ≥ 1     22.4 (30) 21.0 (21)  
DRS ≥ 3 & NSS = 0     9.0 (12)  21.0 (21) 
 DRS ≥ 3 & NSS ≥ 1     24.6 (33) 34.0 (34) 
 
Visit by social relation/family member (O6b) 
DRS 0-2 & NSS = 0     26.8 (15) 38.4 (68)  0.44 
 DRS 0-2 & NSS ≥ 1     23.2 (13) 20.9 (37) 
DRS ≥ 3 & NSS = 0     17.9 (10) 13.0 (23) 
 DRS ≥ 3 & NSS ≥ 1     32.1 (18) 27.7 (49) 
Telephone with social relation/family member (O6c)  
DRS 0-2 & NSS = 0     30.4 (14) 36.7 (69)  0.53 
 DRS 0-2 & NSS ≥ 1     21.7 (10) 21.8 (41) 
DRS ≥ 3 & NSS = 0     10.9 (5)  14.9 (28) 
DRS ≥ 3 & NSS ≥ 1     37.0 (17) 26.6 (50) 
_________________________________________________________________________________________________ 




Table 21.  DRS and NSS scores at Time 1 cross-tabulated  with  social functioning variables, by diagnosis of neith er 
schizophrenia nor mood disorder  
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Patient reports having no confidant (O2a)   No   Yes        
 DRS 0-2 & NSS = 0     40.5 (168) 24.7 (22)  0.10   
DRS 0-2 & NSS ≥ 1     17.6 (73)  23.6 (21)     
 DRS ≥ 3 & NSS = 0     17.8 (74) 14.6 (13)  
 DRS ≥ 3 & NSS ≥ 1     24.1 (100) 37.1 (33) 
Family reports feeling overwhelmed (O2b)    
 DRS 0-2 & NSS = 0     41.1 (124) 33 (67)   0.06 
 DRS 0-2 & NSS ≥ 1     20.2 (61) 16.3 (33) 
DRS ≥ 3 & NSS = 0     15.9 (48) 19.2 (39) 
 DRS ≥ 3 & NSS ≥ 1     22.9 (69) 31.5 (64) 
Visit by social relation/family member (O6b) 
DRS 0-2 & NSS = 0     27.6 (21) 39.5 (169)  0.10 
 DRS 0-2 & NSS ≥ 1     25.0 (19) 17.5 (75) 
DRS ≥ 3 & NSS = 0     14.5 (11) 17.8 (76) 
 DRS ≥ 3 & NSS ≥ 1     32.9 (25) 25.2 (108) 
Telephone with social relation/family member (O6c)  
DRS 0-2 & NSS = 0     35.7 (25) 38.0 (164)  0.88 
 DRS 0-2 & NSS ≥ 1     21.4 (15) 18.1 (78) 
DRS ≥ 3 & NSS = 0     18.6 (13) 17.1 (74) 







Table 22.  DRS and NSS scores at Time 1 cross-tabulated with  treatment modalities [therapy (L3a-d)] and adherenc e with 
treatment (L5), by diagnosis of schizophrenia  
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Therapy (L3a-d)      No   Yes        
  
DRS 0-2 & NSS = 0     43.8 (157) 31.6 (192)  *<.0001 
          
DRS 0-2 & NSS ≥ 1     24.0 (86) 24.9 (151) 
        
 DRS ≥ 3 & NSS = 0     15.6 (56) 13.2 (80) 
         
 DRS ≥ 3 & NSS ≥ 1     16.5 (59) 30.3 (184)  
Adherence with treatment (L5) 
 
DRS 0-2 & NSS = 0     30.7 (54) 37.4 (295)  0.11 
    
DRS 0-2 & NSS ≥ 1     29.6 (52) 23.5 (185) 
     
DRS ≥ 3 & NSS = 0     11.4 (20) 14.7 (116) 
    
DRS ≥ 3 & NSS ≥ 1     28.4 (50) 24.5 (193) 
 
_________________________________________________________________________________________________  





Table 23. DRS and NSS scores at Time 1 cross-tabula ted with treatment modalities [therapy (L3a-d)] and  adherence with 
treatment (L5) by diagnosis of mood disorder 
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Therapy (L3a-d)      No   Yes        
  
DRS 0-2 & NSS = 0     34.1 (124) 28.4(340)  *0.001 
        
DRS 0-2 & NSS ≥ 1     18.1 (66) 13.3 (159) 
         
 DRS ≥ 3 & NSS = 0     15.7 (57) 15.4 (185) 
         
 DRS ≥ 3 & NSS ≥ 1     32.1 (117) 42.9 (514) 
 
Adherence with treatment (L5) 
 
 DRS 0-2 & NSS = 0     27.2 (40) 30.0 (424)  0.53 
    
DRS 0-2 & NSS ≥ 1     18.4 (27) 14.0 (198) 
    
DRS ≥ 3 & NSS = 0     15.7 (23) 15.5 (219) 
    
DRS ≥ 3 & NSS ≥ 1     38.8 (57) 40.6 (574) 
_________________________________________________________________________________________________  






Table 24. DRS and NSS scores at Time 1 cross-tabula ted with treatment modalities [therapy (L3a-d)] and  adherence with 
treatment (L5), by diagnosis of schizophrenia and m ood disorder 
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Therapy (L3a-d)      No   Yes        
  
DRS 0-2 & NSS = 0     43.6 (34) 31.4 (49)  *0.006 
        
DRS 0-2 & NSS ≥ 1     29.5 (23) 18.0 (28)    
        
 DRS ≥ 3 & NSS = 0     10.3 (8)  16.0 (25) 
         
 DRS ≥ 3 & NSS ≥ 1     16.7 (13) 34.6 (54) 
 
Adherence with treatment (L5) 
 
DRS 0-2 & NSS = 0     24.0 (12) 38.6 (71)  0.12 
    
DRS 0-2 & NSS ≥ 1     20.0 (10) 22.3 (41) 
    
DRS ≥ 3 & NSS = 0     22.0 (11) 12.0 (22) 
    
DRS ≥ 3 & NSS ≥ 1     34.0 (17) 27.2 (50)  
_________________________________________________________________________________________________  








Table 25. DRS and NSS scores at Time 1 cross-tabula ted with treatment modalities [therapy (L3a-d)] and  adherence with 
treatment (L5), by diagnosis of neither schizophren ia nor mood disorder 
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Therapy (L3a-d)      No   Yes        
  
DRS 0-2 & NSS = 0     42.0 (58) 36.2 (133)  *0.02  
        
DRS 0-2 & NSS ≥ 1     13.0 (18) 20.7 (76) 
        
 DRS ≥ 3 & NSS = 0     23.2 (32) 15.0 (55) 
         
 DRS ≥ 3 & NSS ≥ 1     21.7 (30) 28.1 (103) 
 
Adherence with treatment (L5) 
 DRS 0-2 & NSS = 0     24.1 (14) 39.6 (177)  *0.03 
    
DRS 0-2 & NSS ≥ 1     19.0 (11) 18.6 (83) 
    
DRS ≥ 3 & NSS = 0     29.3 (17) 15.7 (70) 
    
DRS ≥ 3 & NSS ≥ 1     27.6 (16) 26.2 (117) 
 
_________________________________________________________________________________________________  








Table 26. DRS and NSS scores at Time 1 cross-tabula ted with medication refusal (K2), atypical antipsyc hotic medications, 
typical antipsychotic medications, and both atypica l and typical antipsychotic medications, by diagnos is of schizophrenia  
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Medication refusal (K2)     No   Yes        
 DRS 0-2 & NSS = 0     38.6 (306) 25.0 (43)  *0.006  
DRS 0-2 & NSS ≥ 1     23.2 (184) 30.8 (53) 
 DRS ≥ 3 & NSS = 0     13.4 (106) 17.4 (30) 
 DRS ≥ 3 & NSS ≥ 1     24.8 (196) 26.7 (46) 
Atypical antipsychotic medication 
 DRS 0-2 & NSS = 0     42.9 (190) 30.5 (159)  *<.0001 
DRS 0-2 & NSS ≥ 1     21.4 (95) 27.2 (142) 
 DRS ≥ 3 & NSS = 0     16.5 (73) 12.1 (63) 
 DRS ≥ 3 & NSS ≥ 1     19.2 (85) 30.3 (158) 
Typical antipsychotic medication 
 DRS 0-2 & NSS = 0     37.2 (309) 29.6 (40)  0.20 
DRS 0-2 & NSS ≥ 1     23.5 (195) 31.1 (42) 
 DRS ≥ 3 & NSS = 0     14.2 (118) 13.3 (18) 
 DRS ≥ 3 & NSS ≥ 1     25.1 (208) 25.9 (35) 
Both atypical and typical antipsychotic medication 
DRS 0-2 & NSS = 0     43.0 (177) 26.0 (27)  *0.005   
DRS 0-2 & NSS ≥ 1     20.6 (85) 30.8 (32) 
 DRS ≥ 3 & NSS = 0     17.2 (71) 15.4 (16) 
 DRS ≥ 3 & NSS ≥ 1     19.2 (79) 27.9 (29) 
______________________________________________________________________________________________________ 







Table 27. DRS and NSS scores at Time 1 cross-tabula ted with medication refusal (K2), atypical antipsyc hotic medications, 
typical antipsychotic medications, and both atypica l and typical antipsychotic medications, by diagnos is of mood disorder  
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Medication refusal (K2)     No   Yes        
 DRS 0-2 & NSS = 0     29.5 (421) 30.9 (42)  0.40 
DRS 0-2 & NSS ≥ 1     14.7 (209) 11.8 (16) 
 DRS ≥ 3 & NSS = 0     15.1 (215) 19.9 (27) 
 DRS ≥ 3 & NSS ≥ 1     40.7 (580) 37.5 (51) 
Atypical antipsychotic medication 
 DRS 0-2 & NSS = 0     31.4 (324) 26.4 (140)  0.22 
DRS 0-2 & NSS ≥ 1     13.9 (143) 15.5 (82) 
 DRS ≥ 3 & NSS = 0     14.9 (154) 16.6 (88) 
 DRS ≥ 3 & NSS ≥ 1     39.8 (411) 41.5 (220) 
Typical antipsychotic medication 
 DRS 0-2 & NSS = 0     29.8 (445) 28.8 (19)  0.99 
DRS 0-2 & NSS ≥ 1     14.4 (216) 13.6 (9) 
 DRS ≥ 3 & NSS = 0     15.4 (231) 16.7 (11) 
 DRS ≥ 3 & NSS ≥ 1     40.4 (604) 40.9 (27) 
Both atypical and typical antipsychotic medication 
DRS 0-2 & NSS = 0     31.2 (314) 23.1 (9)   0.64 
DRS 0-2 & NSS ≥ 1     13.8 (139) 12.8 (5) 
 DRS ≥ 3 & NSS = 0     15.0 (151) 20.5 (8) 
 DRS ≥ 3 & NSS ≥ 1     39.9 (401) 43.6 (17) 
______________________________________________________________________________________________________ 






Table 28. DRS and NSS scores at Time 1 cross-tabula ted with medication refusal (K2), atypical antipsyc hotic medications, 
typical antipsychotic medications, and both atypica l and typical antipsychotic medications, by diagnos is of schizophrenia 
and mood disorder 
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Medication refusal (K2)     No   Yes        
 DRS 0-2 & NSS = 0     37.9 (69) 26.9 (14)  *0.005 
DRS 0-2 & NSS ≥ 1     25.3 (46) 9.6 (5)   
 DRS ≥ 3 & NSS = 0     11.5 (21) 23.1 (12) 
 DRS ≥ 3 & NSS ≥ 1     25.3 (46) 40.4 (21) 
Atypical antipsychotic medication 
 DRS 0-2 & NSS = 0     33.3 (37) 37.4 (46)  0.57 
DRS 0-2 & NSS ≥ 1     24.3 (27) 119.5 (24) 
 DRS ≥ 3 & NSS = 0     16.2 (18) 12.2 (15) 
 DRS ≥ 3 & NSS ≥ 1     26.1 (29) 30.9 (38) 
Typical antipsychotic medication 
 DRS 0-2 & NSS = 0     35.3 (73) 37.0 (10)  0.74 
DRS 0-2 & NSS ≥ 1     21.3 (44) 25.9 (7) 
 DRS ≥ 3 & NSS = 0     15.0 (31) 7.4 (2) 
 DRS ≥ 3 & NSS ≥ 1     28.5 (59) 29.6 (8) 
Both atypical and typical antipsychotic medication 
DRS 0-2 & NSS = 0     34.2 (36) 42.9 (9)   0.62 
DRS 0-2 & NSS ≥ 1     21.9 (23) 14.3 (3) 
 DRS ≥ 3 & NSS = 0     17.1 (18) 9.5 (2) 
 DRS ≥ 3 & NSS ≥ 1     26.7 (28) 33.3 (7) 
______________________________________________________________________________________________________ 






Table 29.  DRS and NSS scores at Time 1 cross-tabulated with m edication refusal (K2), atypical antipsychotic medi cations, 
typical antipsychotic medications, and both atypica l and typical antipsychotic medications, by diagnos is of neither 
schizophrenia nor mood disorder  
 
 DRS and NSS scores at Time 1    Percentage (n)    p-value 
_________________________________________________________________________________________________ 
Medication refusal (K2)     No   Yes        
 DRS 0-2 & NSS = 0     38.8 (178) 25.0 (10)  *0.05 
DRS 0-2 & NSS ≥ 1     18.5 (85) 17.5 (7) 
 DRS ≥ 3 & NSS = 0     15.9 (73) 32.5 (13) 
 DRS ≥ 3 & NSS ≥ 1     26.8 (123) 25.0 (10) 
Atypical antipsychotic medication 
 DRS 0-2 & NSS = 0     40.5 (142) 31.8 (49)  0.31 
DRS 0-2 & NSS ≥ 1     18.0 (63) 20.1 (31) 
 DRS ≥ 3 & NSS = 0     16.8 (59) 18.2 (28) 
 DRS ≥ 3 & NSS ≥ 1     24.8 (87) 29.9 (46) 
Typical antipsychotic medication 
 DRS 0-2 & NSS = 0     37.9 (177) 36.8 (14)  0.11 
DRS 0-2 & NSS ≥ 1     18.4 (86) 21.1 (8) 
 DRS ≥ 3 & NSS = 0     16.3 (76) 29.0 (11) 
 DRS ≥ 3 & NSS ≥ 1     27.4 (128) 13.2 (5) 
Both atypical and typical antipsychotic medication 
DRS 0-2 & NSS = 0     40.9 (137) 40.9 (9)   0.57 
DRS 0-2 & NSS ≥ 1     17.9 (60) 22.7 (5) 
 DRS ≥ 3 & NSS = 0     15.8 (53) 22.7 (5) 
 DRS ≥ 3 & NSS ≥ 1     25.4 (85) 13.6 (3) 
______________________________________________________________________________________________________ 





Table 30.  DRS and NSS scores at Time 1 cross-tabulated with i nsight (B2), by the 4 diagnostic groups  
 
 DRS and NSS scores at Time 1    Percentage (n)     p-value 
_________________________________________________________________________________________________ 
Szp       Full  Limited  None      
 DRS 0-2 & NSS = 0    59.6 (59) 32.6 (182) 35.2 (108)  *0.0001 
DRS 0-2 & NSS ≥ 1    16.2 (16) 25.4 (142) 25.7 (79)  
 DRS ≥ 3 & NSS = 0    8.1 (8)  15.7 (88) 13.0 (40)  
 DRS ≥ 3 & NSS ≥ 1    16.2 (16) 26.3 (147) 26.1 (80) 
   
Mood 
 DRS 0-2 & NSS = 0    33.2 (211) 27.2 (219) 28.1 (34)  *0.005 
DRS 0-2 & NSS ≥ 1    13.7 (87) 15.5 (125) 10.7 (13)  
 DRS ≥ 3 & NSS = 0    14.0 (89) 15.0 (121) 26.5 (32)  
 DRS ≥ 3 & NSS ≥ 1    39.1 (248) 42.2 (340) 34.7 (42)  
 
Both szp and mood 
 DRS 0-2 & NSS = 0    43.2 (19) 34.0 (51) 32.5 (13)  0.51  
DRS 0-2 & NSS ≥ 1    25.0 (11) 20.7 (31) 22.5 (9)  
 DRS ≥ 3 & NSS = 0    15.9 (7)  12.7 (19) 17.5 (7)  
 DRS ≥ 3 & NSS ≥ 1    15.9 (7)  32.7 (49) 27.5 (11)  
 
Neither szp nor mood 
DRS 0-2 & NSS = 0    44.3 (66) 35.1 (97) 35.0 (28)  *0.0003 
DRS 0-2 & NSS ≥ 1    14.8 (22) 17.4 (48) 30.0 (24)  
 DRS ≥ 3 & NSS = 0    18.8 (28) 14.5 (40) 23.8 (19)  
 DRS ≥ 3 & NSS ≥ 1    22.2 (33) 33.0 (91) 11.3 (9)  
__________________________________________________________________________________________________________ 
Szp = schizophrenia 





Table 31.  DRS and NSS scores at Time 1 cross-tabulated with C ognitive Performance Scale (CPS 0-3), by the 4 diag nostic 
groups  
 
 DRS and NSS scores at Time 1    Percentage (n)     p-value 
_________________________________________________________________________________________________ 
Szp      0  1  2  3    
 DRS 0-2 & NSS = 0   42.4 (171) 36.3 (103) 23.6 (17) 28.4 (58) *0.005  
DRS 0-2 & NSS ≥ 1   23.8 (96) 24.3 (69) 23.6 (17) 27.0 (55)   
 DRS ≥ 3 & NSS = 0   14.1 (57) 13.7 (39) 19.4 (26) 12.8 (26)    
 DRS ≥ 3 & NSS ≥ 1   19.6 (79) 25.7 (73) 33.3 (24) 31.9 (65) 
   
Mood 
 DRS 0-2 & NSS = 0   31.6 (343) 25.6 (76) 31.2 (19) 22.0 (26) *0.007   
DRS 0-2 & NSS ≥ 1   13.8 (150) 12.5 (37) 18.0 (11) 22.9 (27)   
 DRS ≥ 3 & NSS = 0   15.6 (169) 13.8 (41) 11.5 (7)  21.2 (25)   
 DRS ≥ 3 & NSS ≥ 1   39.0 (424) 48.2 (143) 39.3 (24) 33.9 (40)   
 
Both szp and mood 
 DRS 0-2 & NSS = 0   39.2 (40) 34.4 (22) 31.8 (7)  30.4 (14) 0.72  
DRS 0-2 & NSS ≥ 1   20.6 (21) 18.8 (12) 36.4 (8)  21.7 (10)   
 DRS ≥ 3 & NSS = 0   14.7 (15) 17.2 (11) 4.6 (1)  13.0 (6)   
 DRS ≥ 3 & NSS ≥ 1   25.5 (26) 29.7 (19) 27.3 (6)  34.8 (16)   
 
Neither szp nor mood 
DRS 0-2 & NSS = 0   37.0 (110) 33.3 (24) 48.2 (13) 40.4 (44) *0.02 
DRS 0-2 & NSS ≥ 1   17.5 (52) 11.1 (8)  18.5 (5)  26.6 (29) 
 DRS ≥ 3 & NSS = 0   16.8 (50) 19.4 (14) 7.4 (2)  19.3 (21)   
 DRS ≥ 3 & NSS ≥ 1   28.6 (85) 36.1 (26) 25.9 (7)  13.8 (15)   
__________________________________________________________________________________________________________ 
Szp = schizophrenia 
*Indicates significance at the p < .05 value 
 
 105 
Table 32. Improvement of DRS and NSS scores by the four diagnostic groups 
 
Improvement of DRS and NSS scores  Percentage (n)   p-value 
____________________________________________________________________________ 
      No  Yes 
Szp      41.9 (106) 58.1 (147) 0.24 
Mood      35.0 (167) 65.0 (310) 
Both Szp and mood    31.9 (22) 68.1 (47) 
Neither szp nor mood    38.0 (41) 62.0 (67) 
_____________________________________________________________________________ 
















Table 33. Improvement of DRS and NSS scores cross-t abulated with age group, by the four diagnostic gro ups 
 
Improvement of DRS and NSS scores  Percentage (n)    p-value 
__________________________________________________________________________________ 
      Early onset Adult onset 
Szp 
No     40.0 (16) 42.8 (85)  0.81 
Yes     60.0 (24) 57.9 (117) 
Mood   
No     29.3 (12) 37.2 (146)  0.31 
Yes      70.7 (29) 62.8 (246) 
Both Szp and mood 
No     33.3 (3)  31.5 (17)  0.91 
Yes     66.7 (6)  68.5 (37) 
Neither szp nor mood 
No     40.0 (4)  41.1 (30)  0.95 
Yes      60.0 (6)  58.9 (43) 
_________________________________________________________________________________ 










Table 34. Improvement of DRS and NSS scores cross-t abulated with number of recent psychiatric admissio ns, by the four 
diagnostic groups 
 
Improvement of DRS and NSS scores  Percentage (n)     p-value 
__________________________________________________________________________________ 
      01  12  23  
Szp 
No     37.8 (37) 42.9 (42) 47.4 (27) 0.49     
Yes     62.2 (61) 57.1 (56) 52.6 (30) 
Mood   
No     30.5 (75) 38.6 (61) 42.5 (31) *0.09   
Yes      69.5 (171) 61.4 (97) 57.5 (42) 
Both Szp and mood 
No     36.4 (8)  26.5 (9)  38.5 (5)  0.63   
Yes     63.6 (14) 73.5 (25) 61.5 (8) 
Neither szp nor mood 
No     38.6 (22) 32.3 (10) 45.0 (9)  0.65 
Yes      61.4 (35) 67.7 (21) 55.0 (11) 
__________________________________________________________________________________ 
Szp = schizophrenia 
*Indicates significance at the p < .05 value 
1 = no recent psychiatric admission 
2 = 1-2 recent psychiatric admission 













Table 35. Improvement of DRS and NSS scores cross-t abulated with age at first hospitalization, by the four diagnostic 
groups 
 
Improvement of DRS and NSS scores  Percentage (n)         p-value 
_______________________________________________________________________________________________________ 
      0-14  15-24  25-44  45-54  65+ 
Szp 
No     66.7 (16) 41.9 (49) 28.9 (26) 62.5 (10) 83.3 (5)        *0.0007   
Yes     33.3 (16) 58.1 (68) 71.1 (64) 37.5 (6)  16.7 (1)  
Mood   
No     36.4 (24) 40.4 (44) 33.5 (63) 29.0 (27) 42.9 (9)  0.46 
Yes      63.6 (42) 59.6 (65) 66.5 (125) 71.0 (66) 57.1 (12) 
Both Szp and mood 
No     100.0 (6) 30.8 (8)  20.7 (6) 2 8.6 (2)  0.0 (0)  *0.005 
Yes     0.0 (0)  69.2 (18) 79.3 (23) 71.4 (5)  100.0 (1)  
Neither szp nor mood 
No     40.0 (4)  51.6 (16) 25.6 (10) 26.7 (4)  53.9 (7)  0.13   
Yes      60.0 (6) 4 8.4 (15)  74.4 (29) 73.3 (11) 46.2 (6) 
_______________________________________________________________________________________________________ 
Szp = schizophrenia 









Table 36. Improvement of DRS and NSS scores cross-t abulated with patient reports having no confidant ( O2a), by the four 
diagnostic groups  
 
 Improvement of DRS and NSS scores  Percentage (n)      p-value 
_________________________________________________________________________________________________ 
       No   Yes        
Szp  
No      41.2 (80) 44.1 (26)   0.70 
Yes      58.8 (114) 55.9 (33) 
Mood   
No      32.9 (114) 40.8 (53)   0.11 
Yes       67.2 (233) 59.2 (77) 
Both Szp and mood 
No      27.7 (13) 40.9 (9)    0.27 
Yes      72.3 (34) 59.1 (13) 
Neither szp nor mood 
No      37.5 (33) 40.0 (8)    0.84 
Yes       62.5 (55) 60.0 (12) 
_________________________________________________________________________________________________ 












Table 37. Improvement of DRS and NSS scores cross-t abulated with current in-patient status (A3), by th e four diagnostic 
groups  
 
Improvement of DRS and NSS scores  Percentage (n)    p-value 
___________________________________________________________________________ 
Szp      Voluntary Involuntary      
 No     28.9 (24) 48.2 (82)  *0.004   
Yes     71.1 (59) 51.8 (88) 
   
Mood 
 No     33.1 (90) 37.8 (77)  0.29 
Yes     66.9 (182) 62.3 (127) 
 
Both szp and mood 
 No     35.7 (10) 29.3 (12)  0.57 
Yes     64.3 (18) 70.7 (29) 
 
Neither szp nor mood 
No     40.0 (26) 33.3 (14)  0.49 
Yes     60.0 (39) 66.7 (28) 
___________________________________________________________________________ 
Szp = schizophrenia 








Table 38. Improvement of DRS and NSS scores cross-t abulated with current patient type (Q5), by the fou r diagnostic groups  
 
Improvement of DRS and NSS scores Percentage (n)         p-value 
_________________________________________________________________________________________________ 
Szp      Acute   Longer-term Geriatric Psychiatry Forensinc      
 No     39.8 (78) 47.6 (20) 60.0 (3)   50.0 (5)  0.60 
Yes     60.2 (118) 52.4 (22) 40.0 (2)   50.0 (5) 
   
Mood 
 No     35.8 (150) 23.4 (11) 60.0 (6)   0.0 (0)  0.10 
Yes     64.2 (269) 76.6 (36) 40.0 (4)   100.0 (1)  
 
Both szp and mood 
 No     25.9 (14) 45.5 (5)  100.0 (1)  66.7 (2)  0.13 
Yes     74.1 (40) 54.6 (6)   0.0 (0)   33.3 (1) 
 
Neither szp nor mood 
No     37.8 (28) 30.0 (6)  46.2 (6)   100.0 (1) 0.47 
Yes     62.2 (46) 70.0 (14) 53.9 (7)   0.0 (0) 
_________________________________________________________________________________________________ 












Table 39. Improvement of DRS and NSS scores cross-t abulated with insight (B2), by the four diagnostic groups  
 
Improvement of DRS and NSS scores Percentage (n)        p-value 
_________________________________________________________________________________________________ 
Szp      Full  Limited  None      
 No     50.0 (8)  40.5 (60) 42.7 (38)   0.75 
Yes     50.0 (8)  59.5 (88) 57.3 (51) 
   
Mood 
 No     33.0 (66) 34.6 (84) 50.0 (17)   0.15 
Yes     67.0 (134) 65.4 (159) 50.0 (17) 
 
Both szp and mood 
 No     41.7 (5)  27.9 (12) 35.7 (5)    0.63 
Yes     58.3 (7)  72.1 (31) 64.3 (9) 
 
Neither szp nor mood 
No     35.3 (12) 33.9 (20) 60.0 (9)    0.16 
Yes     64.7 (22) 66.1 (39) 40.0 (6) 
_________________________________________________________________________________________________ 










Table 40. Improvement of DRS and NSS scores cross-t abulated with discharge readiness (P2b 1), by the four diagnostic 
groups  
 
Improvement of DRS and NSS scores Percentage (n)    p-value 
___________________________________________________________________________ 
Szp      No  Yes      
 No     47.7 (51) 37.7 (55) 0.11 
Yes     52.3 (56) 62.3 (91) 
   
Mood 
 No     63.9 (57) 34.5 (110) 0.73 
Yes     63.9 (101) 65.5 (209) 
 
Both szp and mood 
 No     40.0 (12) 25.6 (10) 0.20 
Yes     60.0 (18) 74.4 (29) 
 
Neither szp nor mood 
No     45.5 (15) 34.7 (26) 0.29 
Yes     54.6 (18) 65.3 (49) 
___________________________________________________________________________ 
1P2b = Patient has a support person who is positive towards discharge/maintaining residence in the community 








Table 41. Improvement of DRS and NSS scores cross-t abulated with medication refusal (K2), by the four diagnostic groups  
 
Improvement of DRS and NSS scores Percentage (n)     p-value 
___________________________________________________________________________ 
Szp      No  Yes      
 No     38.7 (77) 52.8 (28)  *0.06 
Yes     61.3 (122) 47.2 (25) 
   
Mood 
 No     34.7 (153) 28.9 (14)  0.61 
Yes     65.3 (288) 61.1 (22) 
 
Both szp and mood 
 No     29.4 (15) 38.9 (7)   0.46 
Yes     70.6 (36) 61.1 (11) 
 
Neither szp nor mood 
No     38.4 (38) 33.3 (3)   0.77 
Yes     61.6 (61) 66.7 (6) 
___________________________________________________________________________ 
Szp = schizophrenia 












Table 42. Improvement of DRS and NSS scores cross-t abulated with atypical antipsychotic medications, b y the four 
diagnostic groups 
 
Improvement of DRS and NSS scores Percentage (n)     p-value 
_____________________________________________________________________________ 
Szp      No  Yes       
No     55.1 (70) 28.6 (36)  **<.0001    
Yes     44.9 (57) 71.4 (90) 
   
Mood    
 No     36.0 (129) 31.9 (38)  0.42 
Yes     64.0 (229) 68.1 (81) 
 
Both szp and mood    
 No     45.0 (18) 13.8 (4)   *0.006 
 Yes     55.0 (22) 86.2 (25) 
 
Neither szp nor mood 
No     34.7 (26) 45.5 (15)  0.29 
Yes     65.3 (49) 54.6 (18) 
_____________________________________________________________________________________ 
Szp = schizophrenia 
*Indicates significance at the p < .05 value 
*Indicates significance at the p < .0001 value 
 
 





Table 43. Improvement of DRS and NSS scores cross-t abulated with typical antipsychotic medications, by  the four 
diagnostic groups 
 
Improvement of DRS and NSS scores Percentage (n)     p-value 
_____________________________________________________________________________ 
Szp      No  Yes       
No     44.4 (96) 27.0 (10)  *0.05    
Yes     55.6 (120) 73.0 (27) 
   
Mood    
 No     35.0 (164) 33.3 (3)   0.92 
Yes     65.0 (304) 66.7 (6)  
 
Both szp and mood    
 No     33.3 (21) 16.7 (1)   0.40 
 Yes     66.7 (42) 83.3 (5) 
 
Neither szp nor mood 
No     36.3 (37) 66.7 (4)   0.14 
Yes     63.7 (65) 33.3 (2) 
_____________________________________________________________________________________ 
Szp = schizophrenia 









Table 44. Improvement of DRS and NSS scores cross-t abulated with both typical and atypical antipsychot ic medications, by 
the four diagnostic groups 
 
Improvement of DRS and NSS scores Percentage (n)     p-value 
_____________________________________________________________________________ 
Szp      No  Yes       
No     57.5 (69) 30.0 (9)   *0.007   
Yes     42.5 (51) 70.0 (21)  
   
Mood    
 No     36.1 (128) 33.3 (2)   0.89 
Yes     63.9 (227) 66.7 (4)   
 
Both szp and mood    
 No     44.7 (17) 0.0 (0)   *0.08 
 Yes     55.3 (21) 100.0 (4)  
 
Neither szp nor mood 
No     35.6 (26) 100.0 (4)  *0.01 
Yes     64.4 (47) 0.0 (0)    
_____________________________________________________________________________________ 
Szp = schizophrenia 









Table 45. Improvement of DRS and NSS scores cross-t abulated with therapy (L3a-d = Individual therapy, group therapy, 
family therapy, and self-help group), by the four d iagnostic groups  
 
Improvement of DRS and NSS scores Percentage (n)     p-value 
___________________________________________________________________________ 
Szp      No  Yes      
 No     52.4 (44) 36.7 (62)  *0.02 
Yes     47.6 (40) 63.3 (107) 
   
Mood 
 No     34.2 (40) 35.3 (127)  0.83 
Yes     65.8 (77) 64.7 (233) 
 
Both szp and mood 
 No     30.0 (6)  32.7 (16)  0.83 
Yes     70.0 (14) 67.4 (33) 
 
Neither szp nor mood 
No     29.2 (7)  40.5 (34)  0.31 
Yes     70.8 (17) 59.5 (50) 
___________________________________________________________________________ 
Szp = schizophrenia 







Table 46. Logistic regression model #1 for improvem ent of DRS and NSS scores 
 
Variables      Parameter estimate (SE)  p-value  OR (CI) 
__________________________________________________________________________________________ 
Intercept       0.93 (0.16)  **<.0001  
Szp1        -0.59 (0.21)  *0.006  0.56 (0.37-0.84) 
Number of recent psychiatric admissions (DD1)2   -0.23 (0.11)  *0.04  0.80 (0.64-0.99) 
Patient reports having no confidant3     -0.34 (0.19)  0.07  0.71 (0.49-1.03) 
Insight (B2)4       -0.26 (0.13)  *0.05  0.77 (0.59-1.00) 
Both typical and atypical antipsychotic medications5  0.81 (0.36)  *0.02  2.24 (1.12-4.50) 
___________________________________________________________________________________________ 
Model fit: x2 = 9.61 df = 8 Hosmer-Lemeshow p = 0.29 
Szp = schizophrenia 
1 = schizophrenia was coded as a dummy variable (compared to the other three diagnostic groups: mood disorders, both schizophrenia and mood 
disorders, and neither schizophrenia nor a mood disorder) 
2 = “number of recent psychiatric admissions” item was coded as a categorical variable: zero recent psychiatric vs. 1 or more recent psychiatric 
admission 
3 = “patient reports having no confidant” item was coded as a categorical variable: no vs. yes 
4 = “insight into mental health” item was coded as a categorical variable: no insight vs. some insight 
5 = this was coded as a categorical variable (patients who were taking a combination of both typical and typical antipsychotic medications were 
compared to those who were taking typical antipsychoti  medications only) 
*Indicates significance at the p < .05 level 










Table 47. Logistic regression model #2 for improvem ent of DRS and NSS scores 
 
Variables      Parameter estimate (SE)  p-value  OR (CI) 
__________________________________________________________________________________________ 
Intercept       0.86 (0.15)  **<.0001   
Szp1        -0.57 (0.21)  *0.007  0.57 (0.37-0.85) 
Number of recent psychiatric admissions (DD1)2   -0.25 (0.11)  *0.03  0.78 (0.63-0.97) 
Insight (B2)3       -0.27 (0.13)  *0.04  0.76 (0.59-0.99) 
Both typical and atypical antipsychotic medications4  0.84 (0.35)  *0.02  2.31 (1.15-4.63) 
_________________________________________________________________________________________ 
Model fit: x2 = 3.31 df = 6 Hosmer-Lemeshow p = 0.77 
Szp = schizophrenia 
1 = schizophrenia was coded as a dummy variable (compared to the other three diagnostic groups: mood disorders, both schizophrenia and mood 
disorders, and neither schizophrenia nor a mood disorder) 
2 = “number of recent psychiatric admissions” item was coded as a categorical variable: zero recent psychiatric vs. 1 or more recent psychiatric 
admission 
3 = “insight into mental health” item was coded as a categorical variable: no insight vs. some insight 
4 = this was coded as a categorical variable (patients who were taking a combination of both typical and typical antipsychotic medications were 
compared to those who were taking typical antipsychoti  medications only) 
*Indicates significance at the p < .05 level 








Appendix 1. Examples of common depressive symptoms,  negative symptoms, and extrapyramidal symptoms.  
____________________________________________________________________________________________ 
Depressive    Negative    Extrapyramidal 
____________________________________________________________________________________________ 
Social withdrawal   Affective flattening   Involuntary movements 
Apathy    Poverty of Speech   Tremors and rigidity  
Anhedonia    Loss of drive or interest   Body restlssness 
Crying and tearfulness  Anhedonia    Muscle contraction 
Negative statements   Reduced interaction   Changes i  breathing and heart rate 
Persistent anger   Lack of motivation 
Repetitive health complaints 
___________________________________________________________________________________________ 




























Adapted from Spreen & Strauss (1998).  A Compendium of Neuropsychological Tests:  
  





Geriatric Depression Scale 
1. Are you basically satisfied with your life?      Y/N 
2. Have you dropped many of your activities and interests?   Y/N 
3. Do you feel that your life is empty?      Y/N 
4. Do you often get bored?       Y/N 
5. Are you hopeful about the future?      Y/N 
6. Are you bothered by thoughts that you can’t get out of your head?  Y/N 
7. Are you in good spirits most of the time?     Y/N 
8. Are you afraid that something bad is going to happen to you?  Y/N 
9. Do you feel happy most of the time?      Y/N 
10. Do you often feel helpless?       Y/N 
11. Do you often get restless and fidgety?     Y/N 
12. Do you prefer to stay home rather than go out and doing new things? Y/N 
13. Do you frequently worry about the future?     Y/N 
14. Do you feel you have more problems with memory than most?  Y/N 
15. Do you think it is wonderful to be alive now?    Y/N 
16. Do you often feel downhearted and blue?     Y/N 
17. Do you feel pretty worthless the way you are now?    Y/N 
18. Do you worry a lot about the past?      Y/N 
19. Do you find life very exciting?      Y/N 
20. Is it hard for you to get started on new projects?    Y/N 
21. Do you feel full of energy?       Y/N 
22. Do you feel that your situation is hopeless?     Y/N 
23. Do you think that most people are better off than you are?   Y/N 
24. Do you frequently get upset about little things?    Y/N 
25. Do you frequently feel like crying?      Y/N 
26. Do you have trouble concentrating?      Y/N 
27. Do you enjoy getting up in the morning?     Y/N 
28. Do you prefer to avoid social gatherings?     Y/N 
29. Is it easy for you to make decisions?      Y/N 




















Adapted from http://www.emoryhealthcare.org/departments/fuqua/CornellScale.pdf 
 
Cornell Scale for Depression in Dementia 
 
Inpatient Nursing Home Resident Outpatient  
Scoring System A = unable to evaluate 0 = absent 1 = mild or intermittent 2 = severe Ratings 
should be based on symptoms and signs occurring during the week prior to interview. No score 
should be given in symptoms result from physical disab lity or illness.  
 
A. Mood-Related Signs  
1. Anxiety: anxious expression, ruminations, worrying     A 0 1 2  
2. Sadness: sad expression, sad voice, tearfulness     A 0 1 2  
3. Lack of reactivity to pleasant events       A 0 1 2  
4. Irritability: easily annoyed, short-tempered      A 0 1 2  
 
B. Behavioral Disturbance  
5. Agitation: restlessness, handwringing, hairpulling     A 0 1 2  
6. Retardation: slow movement, slow speech, slow reactions    A 0 1 2  
7. Multiple physical complaints (score 0 if GI symptoms only)    A 0 1 2  
8. Loss of interest: less involved in usual activities     A 0 1 2 
(score only if change occurred acutely, i.e. in less than 1 month)  
 
C. Physical Signs  
9. Appetite loss: eating less than usual       A 0 1 2 
10. Weight loss (score 2 if greater than 5 lb. in 1month)     A 0 1 2  
11. Lack of energy: fatigues easily, unable to sustain activities    A 0 1 2  
(score only if change occurred acutely, i.e., in less than 1 month)  
 
D. Cyclic Functions  
12. Diurnal variation of mood: symptoms worse in the morning    A 0 1 2  
13. Difficulty falling asleep: later than usual for this individual    A 0 1 2  
14. Multiple awakenings during sleep       A 0 1 2  
15. Early morning awakening: earlier than usual for this individual    
 A 0 1 2  
E. Ideational Disturbance  
16. Suicide: feels life is not worth living, has suicidal wishes,    A 0 1 2  
or makes suicide attempt  
17. Poor self esteem: self-blame, self-depreciation, feelings of failure   A 0 1 2  
18. Pessimism: anticipation of the worst      A 0 1 2  
19. Mood congruent delusions: delusions of poverty, illness, or loss   A 0 1 2 
 
 126 


















Hamilton Rating Scale for Depression 
1. Depressed Mood (Sadness, hopeless, helpless, worthless) 0  1  2  3  4   
2. Feelings of Guilt      0  1  2  3  4 
3. Suicide       0  1  2  3  4 
4. Insomnia Early      0  1  2   
5. Insomnia Middle      0  1  2   
6. Insomnia Late       0  1  2   
7. Work and Activities      0  1  2  3  4 
8. Retardation: Psychomotor     0  1  2  3  4 
9. Agitation       0  1  2  3  4 
10. Anxiety (Psychological)     0  1  2  3  4 
11. Anxiety Somatic      0  1  2  3  4 
12. Somatic Symptoms (Gastrointestinal)   0  1  2   
13. Somatic Symptoms General     0  1  2   
14. Genital Symptoms      0  1  2   
15. Hypochondriasis      0  1  2  3  4 
16. Loss of Weight      0  1  2  3  4 




Appendix 6. Depression Rating Scale and Negative Sy mptom Scale in the RAI-MH 
A.  Depression Rating Scale (DRS) 
 Negative statements 
 Persistent anger 
 Expressions of unrealistic fears 
 Repetitive health complaints 
 Repetitive anxious complaints 
 Facial expression 
 Crying or tearfulness.   
B.  Negative Symptom Scale (NSS) 
 Anhedonia 
 Loss of interest 
 Lack of motivation 
 Reduced interaction 
Coding for the Scales 
 0 - Indicator not exhibited in last 3 days 
 1 - Indicator not exhibited in last 3 days But is reported to be present 
 2 - Indicator exhibited 1-2 days in last 3 days 







Appendix 7 . Sites for the Primary Health Care Transition Fund P roject  
 
MHAP1 MHQI2 Validation3 
 Centre for Addiction 
and Mental Health  
 Credit Valley 
 Grand River Hospital 
 Grey Bruce Health 
Services 
 Homewood Health 
Centre 
 North Bay Psychiatric 
Hospital 
 Queensway Carleton 
 Quinte Health Centre 
 Scarborough General 
 Timmons and District 
 Toronto East 
 
 Brockville Psychiatric 
Hospital 
 Centre for Addiction 
and Mental Health  
 Chatham-Kent Mental 
Health 
 Grand River Hospital 
 Grey Bruce Health 
Services 
 Homewood Health 
Centre 
 Queensway Carleton 
 Quinte Health Centre 
 Timmons and District 
 Toronto East 
 Whitby Mental Health 
 
 Centre for Addiction 
and Mental Health  
 Chatham-Kent Mental 
Health 
 Grand River Hospital 
 Grey Bruce Health 
Services 
 Homewood Health 
Centre 
 North Bay Psychiatric 
Hospital 
 Providence CCC 
 Scarborough General 
 Timmons and District 
 Toronto East 




1 Mental Health Assessment Protocol sub-project in the Primary Health Care Transition Fund. 
2 Mental Health Quality Indicator sub-project in the Primary Health Care Transition Fund. 






















































Appendix 9. Resident Assessment Instrument – Mental  Health ( RAI-MH) 
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